Document:

Corindus Vascular Robotics, Inc. 8-K

 

Exhibit 4.1

 

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES
LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED
UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE
ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

 

WARRANT TO PURCHASE STOCK

 

Company: Corindus Vascular Robotics, Inc., a Delaware
corporation

Number of Shares: [____], subject to adjustment

Type/Series of Stock: Common Stock, $0.0001 par value
per share

Warrant Price: $1.3796 per Share, subject to adjustment

Issue Date: March 14, 2019

Expiration Date: March 13, 2029 See also Section
5.1(b).

Credit Facility: This Warrant
to Purchase Stock (“Warrant”) is issued in connection with that certain First Amendment, of even date
herewith, to that certain Loan and Security Agreement (Term Loan) dated March 16, 2018, among Silicon Valley Bank, Solar Capital
Ltd. and the Company (collectively, and as may be further amended and/or modified and in effect from time to time, the “Loan
Agreement”).

 

THIS WARRANT CERTIFIES
THAT, for good and valuable consideration, [__________] (together with any successor or permitted assignee or transferee of this
Warrant or of any shares issued upon exercise hereof, “Holder”) is entitled to purchase up to the number
of fully paid and non-assessable shares (the “Shares”) of the above-stated Type/Series of Stock (the
“Class”) of the above-named company (the “Company”), at the above-stated Warrant
Price, all as set forth above and subject to the provisions and upon the terms and conditions set forth in this Warrant.

 

SECTION 1. EXERCISE.

 

1.1          Method
of Exercise. Holder may at any time and from time to time exercise this Warrant, in whole or in part, by delivering to the
Company the original of this Warrant together with a duly executed Notice of Exercise in substantially the form attached hereto
as Appendix 1 and, unless Holder is exercising this Warrant pursuant to a cashless exercise set forth in Section 1.2, a check,
wire transfer of same-day funds (to an account designated by the Company), or other form of payment acceptable to the Company for
the aggregate Warrant Price for the Shares being purchased.

 

1.2          Cashless
Exercise. On any exercise of this Warrant, in lieu of payment of the aggregate Warrant Price in the manner as specified in
Section 1.1 above, but otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive Shares equal to
the value of this Warrant, or portion hereof as to which this Warrant is being exercised. Thereupon, the Company shall issue to
the Holder such number of fully paid and non-assessable Shares as are computed using the following formula:

 

X = Y(A-B)/A

 

where:

 

		X =	the number of Shares to be issued to the Holder;

 

     

     

    

 

		Y =	the number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares
surrendered to the Company in payment of the aggregate Warrant Price);

 

		A =	the Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and

 

B =       the
Warrant Price.

 

1.3          Fair
Market Value. If shares of the Class are then traded or quoted on a nationally recognized securities exchange, inter-dealer
quotation system or over-the-counter market (a “Trading Market”), the fair market value of a Share shall
be the closing price or last sale price of a share of the Class reported for the Business Day immediately before the date on which
Holder delivers this Warrant together with its Notice of Exercise to the Company. If shares of the Class are not then traded in
a Trading Market, the Board of Directors of the Company shall determine the fair market value of a Share in its reasonable good
faith judgment.

 

1.4          Delivery
of Certificate and New Warrant. Within a reasonable time after Holder exercises this Warrant in the manner set forth in Section
1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such exercise
(which certificate may be in the form of an electronic certificate or DTC entry, to the extent used by the Company at the time
of such exercise) and, if this Warrant has not been fully exercised and has not expired, a new warrant of like tenor representing
the Shares not so acquired.

 

1.5          Replacement
of Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of
this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form,
substance and amount to the Company or, in the case of mutilation, on surrender of this Warrant to the Company for cancellation,
the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor
and amount.

 

1.6          Treatment
of Warrant Upon Acquisition of Company.

 

(a)          Acquisition.
For the purpose of this Warrant, “Acquisition” means any transaction or series of related transactions
involving: (i) the sale, lease, exclusive license, or other disposition of all or substantially all of the assets of the Company;
(ii) any merger or consolidation of the Company into or with another person or entity (other than a merger or consolidation effected
exclusively to change the Company’s domicile), or any other corporate reorganization, in which the stockholders of the Company
in their capacity as such immediately prior to such merger, consolidation or reorganization, own less than a majority of the Company’s
(or the surviving or successor entity’s) outstanding voting power immediately after such merger, consolidation or reorganization
(or, if such Company stockholders beneficially own a majority of the outstanding voting power of the surviving or successor entity
as of immediately after such merger, consolidation or reorganization, such surviving or successor entity is not the Company); or
(iii) any sale or other transfer by the stockholders of the Company of shares representing at least a majority of the Company’s
then-total outstanding combined voting power.

 

    2

     

    

 

(b)          Treatment
of Warrant at Acquisition. In the event of an Acquisition in which the consideration to be received by the Company’s
stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a “Cash/Public
Acquisition”), and the fair market value of one Share as determined in accordance with Section 1.3 above would be
greater than the Warrant Price in effect on such date immediately prior to such Cash/Public Acquisition, and Holder has not exercised
this Warrant pursuant to Section 1.1 above as to all Shares, then this Warrant shall automatically be deemed to be Cashless Exercised
pursuant to Section 1.2 above as to all Shares effective immediately prior to and contingent upon the consummation of a Cash/Public
Acquisition. In connection with such Cashless Exercise, Holder shall be deemed to have restated each of the representations and
warranties in Section 4 of the Warrant as of the date thereof and the Company shall promptly notify the Holder of the number of
Shares (or such other securities) issued upon exercise. In the event of a Cash/Public Acquisition where the fair market value of
one Share as determined in accordance with Section 1.3 above would be less than the Warrant Price in effect immediately prior to
such Cash/Public Acquisition, then this Warrant will expire immediately prior to the consummation of such Cash/Public Acquisition.

 

(c)          Upon
the closing of any Acquisition other than a Cash/Public Acquisition, the acquiring, surviving or successor entity shall assume
the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities and/or other property
as would have been paid for the Shares issuable upon exercise of the unexercised portion of this Warrant as if such Shares were
outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time in accordance with the
provisions of this Warrant.

 

(d)         As
used in this Warrant, “Marketable Securities” means securities meeting all of the following requirements:
(i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), and is then current in its filing of all required reports
and other information under the Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that
would be received by Holder in connection with the Acquisition were Holder to exercise this Warrant on or prior to the closing
thereof is then traded in a Trading Market, and (iii) following the closing of such Acquisition, Holder would not be restricted
from publicly re-selling all of the issuer’s shares and/or other securities that would be received by Holder in such Acquisition
were Holder to exercise this Warrant in full on or prior to the closing of such Acquisition, except to the extent that any such
restriction (x) arises solely under federal or state securities laws, rules or regulations, and (y) does not extend beyond six
(6) months from the closing of such Acquisition.

 

SECTION 2. ADJUSTMENTS TO THE SHARES
AND WARRANT PRICE.

 

2.1          Stock
Dividends, Splits, Etc. If the Company declares or pays a dividend or distribution on the outstanding shares of the Class payable
in additional shares of the Class or other securities or property (other than cash), then upon exercise of this Warrant, for each
Share acquired, Holder shall receive, without additional cost to Holder, the total number and kind of securities and property which
Holder would have received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company
subdivides the outstanding shares of the Class by reclassification or otherwise into a greater number of shares, the number of
Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the
outstanding shares of the Class are combined or consolidated, by reclassification or otherwise, into a lesser number of shares,
the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased.

 

    3

     

    

 

2.2          Reclassification,
Exchange, Combinations or Substitution. Upon any event whereby all of the outstanding shares of the Class are reclassified,
exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series, then
from and after the consummation of such event, this Warrant will be exercisable for the number, class and series of Company securities
that Holder would have received had the Shares been outstanding on and as of the consummation of such event, and subject to further
adjustment thereafter from time to time in accordance with the provisions of this Warrant. The provisions of this Section 2.2 shall
similarly apply to successive reclassifications, exchanges, combinations, substitutions, replacements or other similar events.

 

2.3          No
Fractional Share. No fractional Share shall be issuable upon exercise of this Warrant and the number of Shares to be issued
shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the Company
shall eliminate such fractional Share interest by paying Holder in cash the amount computed by multiplying the fractional interest
by (i) the fair market value (as determined in accordance with Section 1.3 above) of a full Share, less (ii) the then-effective
Warrant Price.

 

2.4          Notice/Certificate
as to Adjustments. Upon each adjustment of the Warrant Price, Class and/or number of Shares, the Company, at the Company’s
expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price, Class and/or
number of Shares and facts upon which such adjustment is based. The Company shall, upon written request from Holder, furnish Holder
with a certificate of its Chief Financial Officer, including computations of such adjustment and the Warrant Price, Class and number
of Shares in effect upon the date of such adjustment.

 

SECTION 3. REPRESENTATIONS AND COVENANTS
OF THE COMPANY.

 

3.1          Representations
and Warranties. The Company represents and warrants to, and agrees with, the Holder as follows:

 

(a)          All
Shares which may be issued upon the exercise of this Warrant shall,
upon issuance, be duly authorized, validly issued, fully paid and non-assessable,
and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable federal and
state securities laws.

 

(b)         The
Company covenants that it shall at all times cause to be reserved and kept available out of its authorized and unissued capital
stock such number of shares of the Class and other securities as will be sufficient to permit the exercise in full of this Warrant.

 

3.2          Notice
of Certain Events. If the Company proposes at any time to:

 

(a)          declare any dividend
or distribution upon the outstanding shares of the Class, whether in cash, property, stock, or other securities and whether or
not a regular cash dividend;

 

(b)         offer for subscription
or sale pro rata to the holders of the outstanding shares of the Class any additional shares of any class or series of the Company’s
stock (other than pursuant to contractual pre-emptive rights);

 

(c)          effect any reclassification,
exchange, combination, substitution, reorganization or recapitalization of the outstanding shares of the Class; or

 

    4

     

    

 

(d)         effect an Acquisition
or to liquidate, dissolve or wind up;

 

then, in connection with each such event,
the Company shall give Holder notice thereof at the same time and in the same manner as given to holders of the outstanding shares
of the Class.

 

SECTION 4. REPRESENTATIONS, WARRANTIES
OF THE HOLDER.

 

The Holder represents and warrants to the
Company as follows:

 

4.1          Purchase for Own Account.
This Warrant and the Shares to be acquired upon exercise of this Warrant by Holder are being acquired for investment for Holder’s
account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act. Holder
also represents that it has not been formed for the specific purpose of acquiring this Warrant or the Shares.

 

4.2          Disclosure of Information.
Holder is aware of the Company’s business affairs and financial condition and has received or has had full access to all
the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of
this Warrant and its underlying securities. Holder further has had an opportunity to ask questions and receive answers from the
Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional
information (to the extent the Company possessed such information or could acquire it without unreasonable effort or expense) necessary
to verify any information furnished to Holder or to which Holder has access.

 

4.3          Investment Experience.
Holder understands that the purchase of this Warrant and its underlying securities involves substantial risk. Holder has experience
as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such
Holder’s investment in this Warrant and its underlying securities and has such knowledge and experience in financial or business
matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities
and/or has a preexisting personal or business relationship with the Company and certain of its officers, directors or controlling
persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances
of such persons.

 

4.4          Accredited Investor Status.
Holder is an “accredited investor” within the meaning of Regulation D promulgated under the Act.

 

4.5          The Act. Holder understands
that this Warrant and the Shares issuable upon exercise hereof have not been registered under the Act in reliance upon a specific
exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent
as expressed herein. Holder understands that this Warrant and the Shares issued upon any exercise hereof must be held indefinitely
unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from such
registration and qualification are otherwise available. Holder is aware of the provisions of Rule 144 promulgated under the Act.

 

4.6          No Shareholder
Rights. Without limiting any provision of this Warrant, Holder agrees that as a Holder of this Warrant it will not have any
rights (including, but not limited to, voting rights) as a shareholder of the Company with respect to the Shares issuable hereunder
unless and until the exercise of this Warrant and then only with respect to the Shares issued on such exercise.

 

    5

     

    

 

SECTION 5. MISCELLANEOUS.

 

5.1          Term;
Automatic Cashless Exercise Upon Expiration.

 

(a)          Term.
Subject to the provisions of Section 1.6 above, this Warrant is exercisable in whole or in part at any time and from time to time
on or before 6:00 PM, Pacific time, on the Expiration Date and shall be void thereafter.

 

(b)          Automatic
Cashless Exercise upon Expiration. In the event that, upon the Expiration Date, the fair market value of
one Share as determined in accordance with Section 1.3 above is greater than the Warrant Price in effect on such date, then this
Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section 1.2 above as to all Shares for
which it shall not previously have been exercised, and the Company shall, within a reasonable time, deliver a certificate representing
the Shares issued upon such exercise to Holder (which certificate may be in the form of an electronic certificate or DTC entry,
to the extent used by the Company at the time of such exercise).

 

5.2          Legends. Each certificate
evidencing Shares shall be imprinted with a legend in substantially the following form:

 

THE SHARES EVIDENCED BY THIS
CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE
SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE ISSUER TO [__________]
DATED MARCH 14, 2019, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND
LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER
IS EXEMPT FROM SUCH REGISTRATION.

 

5.3          Compliance
with Securities Laws on Transfer. This Warrant and the Shares issued upon exercise of this Warrant may not be transferred or
assigned in whole or in part except in compliance with applicable federal and state securities laws by the transferor and the transferee
(including, without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to
the Company, as reasonably requested by the Company). The Company shall not require Holder to provide an opinion of counsel if
the transfer is to an affiliate of Holder, provided that such affiliate is an “accredited investor” as defined in Regulation
D promulgated under the Act. Additionally, the Company shall also not require an opinion of counsel if there is no material question
as to the availability of Rule 144 promulgated under the Act.

 

5.4          Transfer
Procedure. Subject to the provisions of Section 5.3 and upon providing the Company with written notice, Holder may transfer
all or part of this Warrant to any transferee, provided, however, in connection with any such transfer, Holder will give the Company
notice of the portion of the Warrant being transferred with the name, address and taxpayer identification number of the transferee
and Holder will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder if applicable); and provided
further, that any transferee of this Warrant shall agree in writing with the Company to be bound by all of the terms and conditions
of this Warrant.

 

    6

     

    

 

5.5          Notices.
All notices and other communications hereunder from the Company to the Holder, or vice versa, shall be deemed delivered and effective
(i) when given personally, (ii) on the third (3rd) Business Day after being mailed by first-class registered or certified
mail, postage prepaid, (iii) upon actual receipt if given by facsimile or electronic mail and such receipt is confirmed in writing
by the recipient, or (iv) on the first Business Day following delivery to a reliable overnight courier service, courier fee prepaid,
in any case at such address as may have been furnished to the Company or Holder, as the case may be, in writing by the Company
or such Holder from time to time in accordance with the provisions of this Section 5.5. All notices to Holder shall be addressed
as follows until the Company receives notice of a change of address in connection with a transfer or otherwise:

 

[__________]

[__________]

[__________]

Attention:
[__________]

Email:
[__________]

 

Notice to the Company
shall be addressed as follows until Holder receives notice of a change in address:

 

Corindus Vascular
Robotics, Inc.

Attn: Chief Financial
Officer

309 Waverley Oaks
Road, Suite 105

Waltham, MA 02452

Telephone: (508) 653-3335

Facsimile:

Email:

 

With a copy (which shall not
constitute notice) to:

 

Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C.

Attn: [__________]

One Financial Center

Boston, MA 02111

Telephone: [__________]

Facsimile: [__________]

Email: [__________]

 

5.6          Waiver.
This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in a particular instance
and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such
change, waiver, discharge or termination is sought.

 

5.7          Attorneys’
Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the party prevailing
in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’
fees.

 

    7

     

    

 

5.8          Counterparts;
Facsimile/Electronic Signatures. This Warrant may be executed in counterparts, all of which together shall constitute one and
the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the same extent as an original
signature page with regards to any agreement subject to the terms hereof or any amendment thereto.

 

5.9          Governing
Law. This Warrant shall be governed by and construed in accordance with the laws of the State of California, without giving
effect to its principles regarding conflicts of law.

 

5.10        Headings.
The headings in this Warrant are for purposes of reference only and shall not limit or otherwise affect the meaning of any provision
of this Warrant.

 

5.11        Business
Days. “Business Day” is any day that is
not a Saturday, Sunday or a day on which banks in New York are closed.

 

[Remainder of page left blank intentionally]

[Signature page follows]

 

    8

     

    

 

IN WITNESS WHEREOF, the parties have caused
this Warrant to Purchase Stock to be executed by their duly authorized representatives effective as of the Issue Date written above.

 

	“COMPANY”	 
	 	 
	CORINDUS VASCULAR ROBOTICS, INC.	 
	 	 
	 By:	 	 
	 	 	 
	Name:	 	 
	 	(Print)	 
	 	 	 
	Title:	 	 

 

	“HOLDER”	 
	 	 
	[__________]	 
	 	 
	 By:	 	 
	 	 	 
	Name:	 	 
	 	(Print)	 
	 	 	 
	Title:	 	 

 

    9

     

    

 

APPENDIX 1

 

NOTICE OF EXERCISE

 

1.       The
undersigned Holder hereby exercises its right to purchase ___________ shares of the Common/Series ______ Preferred [circle one]
Stock of __________________ (the “Company”) in accordance with the attached Warrant To Purchase Stock,
and tenders payment of the aggregate Warrant Price for such shares as follows:

 

		☐	check in the amount of $________ payable to order of
the Company enclosed herewith

 

		☐	Wire transfer of immediately available funds to the Company’s
account

 

		☐	Cashless Exercise pursuant to Section 1.2 of the Warrant

 

		☐	Other [Describe] __________________________________________

 

2.       Please
issue a certificate or certificates representing the Shares in the name specified below: 

 

___________________________________________

Holder’s Name 

___________________________________________

 

___________________________________________

(Address)

 

3.      By its execution
below and for the benefit of the Company, Holder hereby restates each of the representations and warranties in Section 4 of the
Warrant to Purchase Stock as of the date hereof.

 

	 	HOLDER: 
	 	 
	 	 

 

	 	By:	 

 

	 	Name:	 

 

	 	Title: 	 

 

	 	(Date): 	 

 

     Appendix 1Corindus Vascular Robotics, Inc. 8-K

Exhibit 10.1

 

SECURITIES
PURCHASE AGREEMENT

 

This
Securities Purchase Agreement (this “Agreement”) is dated as of March 12, 2019, by and between
Corindus Vascular Robotics, Inc., a Delaware corporation (the “Company”), and each Purchaser identified
on Exhibit A hereto (each, including its successors and assigns, a “Purchaser” and collectively,
the “Purchasers”).

 

Recitals

 

A.       This
Agreement is being executed by the Company and each Purchaser in connection with the private placement offering (the “Offering”)
of the common stock, par value $0.0001 per share, of the Company (the “Common Stock”), at the Purchase
Price per share.

 

B.       The
Company and each Purchaser is executing and delivering this Agreement in reliance upon an exemption from securities registration
afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or
Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission
(the “Commission”) under the Securities Act.

 

C.       Each
Purchaser, severally and not jointly, wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated
in this Agreement, that aggregate number of shares of Common Stock, determined as set forth in Section 2.1(a) below
(which aggregate amount for all Purchasers together shall be collectively referred to herein as the “Shares”).

 

D.       Prior
to the Closing, the parties hereto will execute and deliver a Registration Rights Agreement, substantially in the form attached
hereto as Exhibit B (the “Registration Rights Agreement”), pursuant to which, among other
things, the Company will agree to provide, with respect to the Shares, certain registration rights under the Securities Act and
the rules and regulations promulgated thereunder and applicable state securities laws.

 

Now,
Therefore, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the Company and the Purchasers hereby agree as follows:

 

Article
1

DEFINITIONS

 

1.1         Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following
terms shall have the meanings indicated in this Section 1.1:

 

“Action”
means any action, suit, inquiry, notice of violation, proceeding (including any partial proceeding such as a deposition) or investigation
pending or, to the Company’s Knowledge, threatened in writing (or otherwise) against the Company or any of its Subsidiaries
or properties or any officer, director or employee of the Company as of the date hereof acting in his or her capacity as an officer,
director or employee of the Company before or by any federal, state, county, local or foreign court, arbitrator, governmental or
administrative agency, regulatory authority, stock market, stock exchange or trading facility.

 

“Affiliate”
means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, Controls,
is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 144. With
respect to a Purchaser, any investment fund or managed account that is managed on a discretionary basis by the same investment
manager as such Purchaser will be deemed to be an Affiliate of such Purchaser.

 

     

     

    

 

“Agreement”
has the meaning set forth in the preamble.

 

“Applicable
Laws” has the meaning set forth in Section 3.1(o).

 

“Board”
means the Board of Directors of the Company.

 

“Boston
Courts” means the state and federal courts sitting in Boston, Massachusetts.

 

“Business
Day” means any day except Saturday, Sunday, any day which is a federal legal holiday in the United States or any
day on which banking institutions in the Commonwealth of Massachusetts are authorized or required by law or other governmental
action to close.

 

“Closing”
means the closing of the purchase by the Purchasers and sale by the Company of the Shares to such Purchasers pursuant to this Agreement.

 

“Closing
Date” means the Trading Day when all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all of the conditions set forth in Sections 2.1, 2.2, 5.1 and 5.2 hereof are satisfied or waived by the Purchasers
holding or having the right to acquire at least a majority of the Shares to be purchased at the Closing or then outstanding, as
the case may be, or such other date as the Company and such Purchasers may agree.

 

“Commission”
has the meaning set forth in the Recitals.

 

“Common
Stock” has the meaning set forth in the Recitals.

 

“Company”
has the meaning set forth in the preamble.

 

“Company
Counsel” means Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., with offices located at One Financial Center,
Boston, Massachusetts 02111.

 

“Company
Deliverables” has the meaning set forth in Section 2.2(a).

 

“Company
Product” has the meaning set forth in Section 3.1(p).

 

“Company’s
Knowledge” means with respect to any statement made to the knowledge of the Company, that the statement is based
upon the actual knowledge of the officers of the Company who, as of the date hereof, have responsibility for the matter or matters
that are the subject of the statement, and the knowledge that each such person would have reasonably obtained in the performance
of each such person’s duties as an officer of the Company.

 

“Compliance
Certificate” has the meaning set forth in Section 2.2(a)(vi).

 

“Control”
(including the terms “controlling”, “controlled” by or “under common
control with”) means the possession, direct or indirect, of the power to direct or cause the direction of the management
and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.

 

“Covered
Persons” has the meaning set forth in Section 3.1(ll).

 

“Disclosure
Materials” has the meaning set forth in Section 3.1(h).

 

    2

     

    

 

“Disclosure
Schedule” has the meaning set forth in Section 3.1.

 

“Disqualification
Events” has the meaning set forth in Section 3.1(ll).

 

“DTC”
has the meaning set forth in Section 4.1(d).

 

“Environmental
Laws” has the meaning set forth in Section 3.1(l).

 

“Evaluation
Date” has the meaning set forth in Section 3.1(u).

 

“ERISA”
has the meaning set forth in Section 3.1(ii).

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations
promulgated thereunder.

 

“FDA”
has the meaning set forth in Section 3.1(o).

 

“GAAP”
means U.S. generally accepted accounting principles, as applied by the Company.

 

“Indemnified
Person” has the meaning set forth in Section 4.8(b).

 

“Intellectual
Property” has the meaning set forth in Section 3.1(r).

 

“Irrevocable
Transfer Agent Instructions” means, with respect to the Company, the Irrevocable Transfer Agent Instructions, in
the form of Exhibit E, executed by the Company and delivered to and acknowledged in writing by the Transfer Agent.

 

“Lien”
means any material lien, charge, claim, encumbrance, security interest, right of first refusal, preemptive right or other restrictions
of any kind.

 

“Material
Adverse Effect” means a material adverse effect on the (i) validity or enforceability of, or the Company’s
ability to perform in any material respect its obligations under, this Agreement or (ii) earnings, results of operations, assets,
properties, business or condition (financial or otherwise) of the Company and its subsidiaries, taken as a whole, except that any
of the following, either alone or in combination, shall not be deemed a Material Adverse Effect: (i) effects caused by changes
or circumstances affecting general market conditions in the U.S. or applicable foreign economy or effects generally applicable
to the industry in which the Company operates, (ii) effects resulting from or relating to the announcement or disclosure of
the sale of the Shares or other transactions contemplated by this Agreement, (iii) effects caused by any event, occurrence
or condition resulting from or relating to the taking of any action in accordance with this Agreement, (iv) changes
in the trading price or trading volume of the Company’s Common Stock (but not the underlying causes thereof), (v)
the filing of any stockholder or derivative litigation arising from or relating
to the execution of this Agreement or the consummation of the transactions contemplated hereby, or (vi) effects caused by earthquakes,
hostilities, acts of war, sabotage or terrorism or military actions or any escalation or material worsening of any such hostilities,
acts of war, sabotage or terrorism or military actions existing as of the date hereof, except, with respect to clauses (i) and
(vi), to the extent that the effects of such changes or events are disproportionately adverse to the earnings, results of
operations, assets, properties, business or condition (financial or otherwise) of the Company and its subsidiaries, taken as a
whole.

 

“Material
Contract” means any contract of the Company that has been filed as an exhibit to the SEC Reports pursuant to Item 601(b)(4)
or Item 601(b)(10) of Regulation S-K.

 

    3

     

    

 

“Material
Permits” has the meaning set forth in Section 3.1(p).

 

“Money
Laundering Laws” has the meaning set forth in Section 3.1(ff).

 

“Outside
Date” means the tenth (10th) Business Day following the date of this Agreement.

 

“Person”
means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company,
joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically
listed herein.

 

“Principal
Trading Market” means the Trading Market on which the Common Stock is primarily listed on or quoted for trading,
which, as of the date of this Agreement and the Closing Date, shall be the NYSE American.

 

“Proceeding”
means an Action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding,
such as a deposition).

 

“Purchase
Price” means $1.3796.

 

“Purchaser”
or “Purchasers” has the meaning set forth in the preamble.

 

“Purchaser
Deliverables” has the meaning set forth in Section 2.2(b).

 

“Purchaser
Party” has the meaning set forth in Section 4.8(a).

 

“Registration
Rights Agreement” has the meaning set forth in the recitals.

 

“Registration
Statement” means a registration statement meeting the requirements set forth in the Registration Rights Agreement
and covering the resale by the Purchasers of the Registrable Securities (as defined in the Registration Rights Agreement).

 

“Regulation
D” has the meaning set forth in the Recitals.

 

“Required
Approvals” has the meaning set forth in Section 3.1(e).

 

“Rule 144”
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

“Sanctions”
has the meaning set forth in Section 3.1(gg).

 

“Sanctioned
Persons” has the meaning set forth in Section 3.1(gg).

 

“Sanctioned
Country” and “Sanctioned Countries” have the meanings set forth in Section 3.1(gg).

 

“SEC Reports”
has the meaning set forth in Section 3.1(h).

 

“Secretary’s
Certificate” has the meaning set forth in Section 2.2(a)(vi).

 

“Securities
Act” has the meaning set forth in the recitals.

 

“Shares”
has the meaning set forth in the Recitals.

 

    4

     

    

 

“Short
Sales” include, without limitation, (i) (A) all “short sales” as defined in Rule 200 promulgated
under Regulation SHO under the Exchange Act, whether or not against the box, and (B) all types of direct and indirect stock
pledges, forward sale contracts, options, puts, calls, short sales, swaps, “put equivalent positions” (as defined in
Rule 16a-1(h) under the Exchange Act) and similar arrangements (including on a total return basis) that have an economically
similar result to a “short sale” as defined in Rule 200, and (ii) sales and other transactions through non-U.S.
broker dealers or foreign regulated brokers that have an economically similar result to a “short sale” as defined in
Rule 200.

 

“Solicitor”
has the meaning set forth in Section 3.1(ll).

 

“Stock
Certificates” has the meaning set forth in Section 2.2(a)(iv).

 

“Subscription
Amount” has the meaning set forth in Section 2.1(a).

 

“Subsidiary”
means any entity in which the Company, directly or indirectly, owns capital stock or holds an equity or similar interest.

 

“Trading
Affiliate” has the meaning set forth in Section 3.2(h).

 

“Trading
Day” means (i) a day on which the Common Stock is listed or quoted and traded on its Principal Trading Market
(unless the Principal Trading Market is the OTC Bulletin Board or the OTC Pink tier of the OTC Markets Group, Inc.), or (ii) if
the Common Stock is not listed on a Trading Market (other than the OTC Bulletin Board or the OTC QB, OTC QX or OTC Pink tier of
the OTC Markets Group, Inc.), a day on which the Common Stock is traded in the over-the-counter market, as reported by the OTC
Bulletin Board, or (iii) if the Common Stock is not quoted on any Trading Market (other than the OTC QB, OTC QX or OTC Pink
tier of the OTC Markets Group, Inc.), a day on which the Common Stock is quoted in the over-the-counter market as reported by the
OTC QB, OTC QX or OTC Pink tier of the OTC Markets Group, Inc. (or any similar organization or agency succeeding to its functions
of reporting prices); provided, that in the event that the Common Stock is not listed or quoted as set forth in (i), (ii) and
(iii) hereof, then Trading Day shall mean a Business Day.

 

“Trading
Market” means whichever of the New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, the Nasdaq
Global Market, the Nasdaq Capital Market, the OTC Bulletin Board, the OTC QB, OTC QX or OTC Pink tier of the OTC Markets Group,
Inc. (or any similar organization or agency succeeding to its functions of reporting prices) on which the Common Stock is listed
or quoted for trading on the date in question.

 

“Transaction
Documents” means this Agreement, the Registration Rights Agreement, the annexes and exhibits attached hereto and
thereto, the Irrevocable Transfer Agent Instructions and any other documents or agreements executed in connection with the transactions
contemplated hereunder.

 

“Transfer
Agent” means Manhattan Transfer Registrar Company, with a mailing address of 57 Eastwood Road, Miller Place, NY 11764,
or any successor transfer agent for the Company.

 

“Voting
Debt” has the meaning set forth in Section 3.1(g).

 

    5

     

    

 

Article
2

PURCHASE AND SALE

 

2.1        
Closing.

 

(a)         
Subject to the terms and conditions set forth in this Agreement, at the Closing, the Company shall issue and sell to
each Purchaser, and each Purchaser shall, severally and not jointly, purchase from the Company, such number of Shares equal to
the quotient resulting from dividing (i) the Subscription Amount for such Purchaser, as indicated opposite such Purchaser’s
name on Exhibit A hereto (the “Subscription Amount”), by (ii) the Purchase Price, rounded
down to the nearest whole Share.

 

(b)         
The Closing of the purchase and sale of the Shares shall take place at the offices of Company Counsel on the Closing
Date or at such other location(s) or remotely by electronic means as the Company and the Purchasers holding or having the right
to acquire at least a majority of the Shares to be purchased at the Closing mutually agree.

 

(c)         
On the Closing Date, the Company shall deliver to each Purchaser (or its designated custodian in accordance with its
delivery instructions) a Stock Certificate (as defined below) representing the Shares being purchased by such Purchaser hereunder
(registered in the name of such Purchaser or its nominee as set forth on the Stock Certificate Questionnaire) or evidence of a
book entry position, free and clear of all restrictive and other legends or instructions (except as expressly provided in Section
4.1(c) hereof), evidencing the number of Shares such Purchaser is purchasing hereunder, in each case against payment by the
Purchaser of its applicable Subscription Amount, in United States dollars and in immediately available funds, by wire transfer
to a bank account designated by the Company. Notwithstanding anything to the contrary set forth herein, no Purchaser shall be required
to pay its Subscription Amount for the Shares being purchased by such Purchaser until it (or its designated custodian as set forth
on the Stock Certificate Questionnaire) confirms receipt of a Stock Certificate or evidence of a book entry position evidencing
the Shares being purchased hereunder.

 

2.2        
Closing Deliveries.

 

(a)         
On or prior to the Closing, the Company shall issue, deliver or cause to be delivered or made available to each Purchaser
the following (the “Company Deliverables”):

 

(i)         
this Agreement, duly executed by the Company;

 

(ii)        
a legal opinion of Company Counsel dated as of the Closing Date, in substantially the form attached hereto as Exhibit
D, executed by such counsel and addressed to the Purchasers;

 

(iii)       
the Registration Rights Agreement, duly executed by the Company;

 

(iv)       
one or more stock certificates, free and clear of all restrictive and other legends, except as provided in Section 4.1(c)
hereof, evidencing the Shares subscribed for by the Purchasers hereunder to be registered in the name of such Purchasers as set
forth on the Stock Certificate Questionnaire included as Exhibit C-2 hereto (the “Stock Certificates”)
and delivered to the Company pursuant to Section 2.2(b)(iv);

 

(v)         
a certificate of the Secretary of the Company (the “Secretary Certificate”), dated as of the
Closing Date, (a) certifying the resolutions adopted by the Board of Directors of the Company and any duly authorized committee
thereof approving the transactions contemplated by this Agreement and the other Transaction Documents and the issuance of the Shares,
(b) certifying the current versions of the certificate of incorporation, as amended, and bylaws of the Company and (c) certifying
as to the signatures and authority of persons signing the Transaction Documents and related documents on behalf of the Company,
in substantially the form attached hereto as Exhibit F;

 

    6

     

    

 

(vi)       
a certificate (the “Compliance Certificate”), dated as of the Closing Date and signed by the
Company’s Chief Executive Officer or its Chief Financial Officer, certifying to the fulfillment of the conditions specified
in Sections 5.1(a) and (b), in substantially the form attached hereto as Exhibit G;

 

(vii)      
a certificate evidencing the formation and good standing of the Company issued by the Secretary of State of the State
of Delaware, as of a date within five (5) days of the Closing Date; and

 

(viii)     
a certified copy of the Certificate of Incorporation, as certified by the Secretary of State of the State of Delaware,
as of a date within ten (10) days of the Closing Date.

 

(b)         
On or prior to the Closing, each Purchaser shall deliver or cause to be delivered to the Company the following (the
“Purchaser Deliverables”):

 

(i)          
this Agreement, duly executed by such Purchaser;

 

(ii)         
the Registration Rights Agreement, duly executed by such Purchaser;

 

(iii)       
its Subscription Amount, in United States dollars and in immediately available funds, by wire transfer to the account
provided by the Company;

 

(iv)       
a fully completed and duly executed Selling Stockholder Questionnaire in the form attached as Annex B to the Registration
Rights Agreement;

 

(v)         
a fully completed and duly executed Accredited Investor Questionnaire in the form attached hereto as Exhibit C-1;
and

 

(vi)        
a fully completed and duly executed Stock Certificate Questionnaire in the form attached hereto as Exhibit C-2.

 

Article
3

REPRESENTATIONS AND WARRANTIES

 

3.1        
Representations and Warranties of the Company. The Company hereby represents and warrants as of the date hereof and
the Closing Date (except for the representations and warranties that speak as of a specific date, which shall be made as of such
date) to each of the Purchasers that except as disclosed in the SEC Reports and the disclosure schedule delivered by the Company
hereunder (the “Disclosure Schedule”), which disclosure shall be deemed a part of this Article
3 and shall qualify any representations and warranties made by the Company herein to the extent of the applicable disclosure:

 

(a)         
Subsidiaries. Except as set forth on Section 3.1(a) of the Disclosure Schedule, the Company has no direct or
indirect Subsidiaries other than Corindus, Inc., a Delaware corporation and wholly-owned subsidiary of the Company, and Corindus
Security Corporation, a Delaware corporation and wholly-owned subsidiary of the Company. The Company owns, directly or indirectly,
all of the capital stock or comparable equity interests of each Subsidiary free and clear of any and all Liens, and all the issued
and outstanding shares of capital stock or comparable equity interest of each Subsidiary are validly issued and are fully paid
and non-assessable.

 

    7

     

    

 

(b)         
Organization and Qualification. The Company and each Subsidiary is an entity duly incorporated, validly existing and
in good standing under the laws of the jurisdiction of its incorporation, with the requisite corporate power and authority to own
or lease and use its properties and assets and to carry on its business as currently conducted. The Company and its Subsidiaries
are not in violation of any of the provisions of their certificate of incorporation or bylaws. The Company and each of its Subsidiaries
are duly qualified to conduct business and are in good standing as a foreign corporation or other entity in each jurisdiction in
which the nature of the business conducted or property owned by them makes such qualification necessary, except where the failure
to be so qualified or in good standing, as the case may be, would not reasonably be expected to result in a Material Adverse Effect.

 

(c)         
Authorization; Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and
to consummate the transactions contemplated by each of the Transaction Documents to which it is a party and otherwise to carry
out its obligations hereunder and thereunder. The execution and delivery of each of the Transaction Documents to which it is a
party by the Company and the consummation by it of the transactions contemplated hereby and thereby (including, but not limited
to, the sale and delivery of the Shares) have been duly authorized by all necessary corporate action on the part of the Company,
and no further corporate action is required by the Company, its Board or its stockholders in connection therewith other than in
connection with the Required Approvals. Each of the Transaction Documents to which it is a party has
been (or upon delivery will have been) duly executed by the Company and is, or when delivered in accordance with the terms hereof,
will constitute the legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms,
except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar
laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies or by other equitable principles
of general application or insofar as indemnification and contribution provisions may be limited by applicable law. There are no
shareholder agreements, voting agreements, or other similar arrangements with respect to the Company’s capital stock (i)
to which the Company is a party or, (ii) to the Company’s Knowledge, between or among any of the Company’s stockholders.

 

(d)         
Non Contravention. The execution, delivery and performance by the Company of the Transaction Documents to which it is
a party and the consummation by the Company of the transactions contemplated hereby or thereby (including, without limitation,
the issuance of the Shares) do not and will not (i)  violate any provisions of the Company’s or its Subsidiaries’
certificate of incorporation or bylaws, (ii) constitute a default (or an event that with notice or lapse of time or both would
become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or give to others
any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any indenture,
contract, lease, mortgage, deed of trust, note agreement, loan agreement or other agreement, obligation, condition, covenant or
instrument to which the Company or any of its Subsidiaries is a party or bound or to which its or their property is subject or
(iii) subject to the Required Approvals, conflict with, result in a violation of, or imposition of any Lien, upon any property
or assets of the Company pursuant to any law, rule, regulation, order, judgment, injunction, decree or other restriction of any
court, regulatory body, administrative agency, governmental authority, arbitrator or other authority to which the Company or its
Subsidiaries are subject (including federal and state securities laws and regulations and the rules and regulations, assuming the
correctness of the representations and warranties made by the Purchasers herein, of any self-regulatory organization to which the
Company or its securities are subject, including all applicable Trading Markets), or by which any property or asset of the Company
is bound or affected), except in the case of clause (ii) and clause (iii) such as would not individually reasonably be
expected to have a Material Adverse Effect.

 

    8

     

    

 

(e)         
Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, approval, authorization
or order of, qualification, designation, declaration, give any notice to, or make any filing or registration with, any court or
other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance
by the Company of the Transaction Documents (including the issuance of the Shares), other than (i) the filing with the Commission
of one or more Registration Statements in accordance with the requirements of the Registration Rights Agreement, (ii) filings
required by applicable state securities laws after the date hereof, (iii) the filing of a Notice of Sale of Securities on
Form D with the Commission under Regulation D of the Securities Act, (iv) the filing of any requisite notices and/or
application(s) to the Principal Trading Market for the issuance and sale of the Shares and the listing of the Shares for trading
or quotation, as the case may be, thereon in the time and manner required thereby (which will be made and approved prior to the
Closing), (v) the filings required in accordance with Section 4.6 of this Agreement and (vi) those that have
been made or obtained prior to the date of this Agreement satisfying the requirements thereof (collectively, the “Required
Approvals”).

 

(f)         
Issuance of the Securities. The Shares have been duly authorized and, when issued and paid for in accordance with the
terms of the Transaction Documents, will be duly and validly issued, fully paid and non-assessable and free and clear of all Liens,
other than restrictions on transfer provided for in the Transaction Documents or imposed by applicable securities laws, and shall
not be subject to preemptive or similar rights. Assuming the accuracy of the representations and warranties
of the Purchasers in this Agreement, the Shares will be issued in compliance with all applicable federal and state securities laws.

 

(g)        
Capitalization. The capitalization of the Company is as described in the SEC Reports, except (i) as set forth on Section
3.1(g) of the Disclosure Schedule and (ii) for issuances pursuant to this Agreement, stock option exercises, issuances pursuant
to equity incentive plans or exercises of warrants. The Company has not issued any capital stock since the date of its most recently
filed SEC Report other than to reflect stock option and warrant exercises that do not, individually or in the aggregate, have a
material effect on the issued and outstanding capital stock, options and other securities of the Company. No Person has any right
of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated
by the Transaction Documents that have not been effectively waived as of the Closing Date. Except as set forth on Section 3.1(g)
of the Disclosure Schedule, there are no bonds, debentures, notes or other indebtedness having general voting rights (or convertible
into securities having such rights) (“Voting Debt”) and no outstanding options, warrants, calls, subscriptions
or other rights, agreements, arrangements or commitments relating to the issued or unissued capital stock of the Company, obligating
the Company to issue, transfer, sell, redeem, purchase, repurchase or otherwise acquire or cause to be issued, transferred, sold,
redeemed, purchased, repurchased or otherwise acquired any capital stock or Voting Debt of, or other equity interests in, the Company
or securities or rights convertible into or exchangeable for such shares or equity interests or obligations of the Company to grant,
extend or enter into any such option, warrant, call, subscription or other right, arrangement or commitment. Except as set forth
on Section 3.1(g) of the Disclosure Schedule, the issuance and sale of the Shares will not obligate the Company to issue
shares of Common Stock or other securities to any Person (other than the Purchasers) and will not trigger any anti-dilution or
price adjustment rights. All of the outstanding shares of capital stock of the Company are validly issued, fully paid and nonassessable,
have been issued in compliance in all material respects with all applicable federal and state securities laws, and none of such
outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities which
violation would have or would reasonably be expected to result in a Material Adverse Effect. Except as set forth on Section
3.1(g) of the Disclosure Schedule, there are no registration rights, stockholders agreements, voting agreements or other similar
agreements with respect to the Company’s capital stock to which the Company is a party or, to the Company’s Knowledge,
between or among any of the Company’s stockholders.

 

    9

     

    

 

(h)        
SEC Reports. The Company has filed all reports, schedules, forms, statements and other documents required to be filed
by it under the Exchange Act, including pursuant to Section 13, 14(a) and 15(d) thereof, for twelve (12) months preceding and including
the Closing Date (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being
collectively referred to herein as the “SEC Reports” and together with this Agreement, including
the Disclosure Schedule hereto, each as amended and supplemented to date, the “Disclosure Materials”),
on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior
to the expiration of any such extension. As of their respective filing dates (or, if amended prior to the date of this Agreement,
when amended), all SEC Reports complied in all material respects with the requirements of the Exchange Act and the rules and
regulations of the Commission promulgated thereunder.  None of the SEC Reports as of their respective dates contained any
untrue statement of material fact or omitted to state a material fact required to be stated therein or necessary to make the statements
made therein, in light of the circumstances under which they were made, not misleading. There is no transaction, arrangement, or
other relationship between the Company (or any Subsidiary) and any unconsolidated or other off balance sheet entity that is required
to be disclosed by the Company in its Exchange Act filings that is not so disclosed. Each franchise, contract or other document
of a character required to be described in the SEC Reports or to be filed as an exhibit to the SEC Reports under the Securities
Act and the rules and regulations promulgated thereunder is so described or filed.

 

(i)          
Financial Statements. The consolidated financial statements of the Company included in the SEC Reports comply in all
material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto
as in effect at the time of filing. Such financial statements have been prepared in accordance with GAAP applied on a consistent
basis during the periods involved, except as may be otherwise specified in such financial statements or the notes thereto, and
fairly present in all material respects the consolidated financial position of the Company and its consolidated Subsidiaries taken
as a whole as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in
the case of unaudited statements, to normal, year-end audit adjustments. As of the date hereof, there are no disagreements between
the Company and its independent accounting firm on any matter of accounting principles or practices, financial statement disclosure,
or auditing scope or procedure relating to the Company’s fiscal 2018 audit or otherwise that, if not resolved to the satisfaction
of the accounting firm, would result in the accounting firm referencing such disagreement in its audit report for such fiscal year.

 

(j)         
Tax Matters. The Company and each of its Subsidiaries (i) has prepared and filed all foreign, federal and state
income and all other tax returns, reports and declarations required to be filed prior to the date hereof by any jurisdiction to
which it is subject, which are correct and complete in all material respects for the periods to which such tax returns relate,
(ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to
be due prior to the date hereof on such returns, reports and declarations, except those being contested in good faith, with respect
to which adequate reserves have been set aside on the books of the Company and (iii) has set aside on its books provisions
reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations
apply, except where the failure to so file or pay or set aside provisions for any such tax, assessment, charge or return would
not reasonably be expected to have a Material Adverse Effect. There are in effect no waivers of applicable statutes of limitations
with respect to taxes for any year.

 

    10

     

    

 

(k)        
Material Changes. Since the date of the latest balance sheet included in the financial statements contained within the
SEC Reports, except as specifically disclosed in the SEC Reports (i) there have been no events, occurrences or developments
that have had or would reasonably be expected to have a Material Adverse Effect, (ii) the Company has not incurred any material
liabilities (contingent or otherwise) other than (A) trade payables, accrued expenses and other liabilities incurred in the
ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s
financial statements pursuant to GAAP or to be disclosed in filings made with the Commission, (iii) the Company has not materially
altered its method of accounting or the manner in which it keeps its accounting books and records, (iv) the Company has not
declared or made any dividend or distribution of cash or other property to its stockholders, other than the quarterly dividends
payable on the Company’s outstanding shares of Series A Convertible Preferred Stock, $0.0001 par value per share, or purchased,
redeemed or made any agreements to purchase or redeem any shares of its capital stock (other than in connection with repurchases
of unvested stock issued to employees of the Company), (v) the Company has not issued any equity securities to any officer,
director or Affiliate, except Common Stock or other equity securities issued in the ordinary course pursuant to existing Company
stock option or stock purchase plans or executive and director corporate arrangements disclosed in the SEC Reports, (vi) there
has not been any material change or amendment to, or any waiver of any material right under, any Material Contract under which
the Company or any of its assets is bound or subject, and (vii) there have not been any changes in the authorized capital, assets,
liabilities, financial condition, business or operations of the Company from that reflected in the latest financial statements
contained in the SEC Reports except changes in the ordinary course of business which have not had or would not reasonably be expected
to have, either individually or in the aggregate, a Material Adverse Effect. Except as set forth
on Section 3.1(k) of the Disclosure Schedule, neither the Company nor any of its Subsidiaries has taken any steps to seek
protection pursuant to any law or statute relating to bankruptcy, insolvency, reorganization, receivership, liquidation or winding
up, nor does the Company or any Subsidiary have any knowledge or reason to believe that any of their respective creditors intend
to initiate involuntary bankruptcy proceedings or any actual knowledge of any fact which would reasonably lead a creditor to do
so.

 

(l)         
Environmental Matters. To the Company’s Knowledge, the Company (i) is not in violation of any statute, rule,
regulation, decision or order of any governmental agency or body or any court, domestic or foreign, relating to the use, disposal
or release of hazardous or toxic substances or relating to the protection or restoration of the environment or human exposure to
hazardous or toxic substances (collectively, “Environmental Laws”), (ii) does not own or operate
any real property contaminated with any substance that is in violation of any Environmental Laws, (iii) is not liable for
any off-site disposal or contamination pursuant to any Environmental Laws, and (iv) is not subject to any claim relating to
any Environmental Laws; which violation, contamination, liability or claim has had or would have a Material Adverse Effect; and
there is no pending or, to the Company’s Knowledge, threatened investigation that might lead to such a claim. The Company
and each of its Subsidiaries have received and are in compliance with all permits, licenses or other approvals required of them
under applicable Environmental Laws to conduct its business, except where such non-compliance or failure to receive required permits,
licenses or other approvals would not, individually or in the aggregate, have or reasonably be expected to have a Material Adverse
Effect. Neither the Company nor any of its Subsidiaries has been named as a “potentially responsible party” under the
Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended.

 

(m)       
Litigation. There is no Action which (i) adversely affects or challenges the legality, validity or enforceability
of any of the Transaction Documents or the Shares, or (ii) would reasonably be expected to have, individually or in the aggregate,
a Material Adverse Effect. Neither the Company nor any Subsidiary, nor to the Company’s Knowledge any director or officer
thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities
laws or a claim of breach of fiduciary duty. There has not been, and to the Company’s Knowledge there is not pending or contemplated,
any investigation by the Commission involving the Company or, to the Company’s Knowledge, any current or former director
or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any
registration statement filed by the Company or any of its Subsidiaries under the Exchange Act or the Securities Act. There are
no outstanding orders, judgments, injunctions, awards or decrees of any court, arbitrator or governmental or regulatory body against
the Company or, to the Company’s Knowledge, any executive officers or directors of the Company in their capacities as such,
which individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect.

 

    11

     

    

 

(n)        
Employment Matters. No labor dispute exists or, to the Company’s Knowledge, is imminent with respect to any of
the employees of the Company or its Subsidiaries or any of its principal suppliers or contractors which would have a Material Adverse
Effect. None of the Company’s employees is a member of a union that relates to such employee’s relationship with the
Company, and the Company is not a party to a collective bargaining agreement.

 

(o)        
Compliance. The Company and its Subsidiaries (i) are not in default under or in violation of (and no event has
occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or its Subsidiaries),
nor has the Company or any of its Subsidiaries received written notice of a claim that it is in default under or that it is in
violation of, any indenture, loan or credit agreement or any other Material Contract (whether or not such default or violation
has been waived), (ii) are not in violation of any order of any court, arbitrator or governmental body having jurisdiction
over the Company, its Subsidiaries or their properties or assets; and (iii) are in compliance with, and have not receipted
notice that they are in violation of, all statutes, laws, ordinances, rules and regulations applicable to the Company and
its Subsidiaries or to the Company Products (“Applicable Laws”), including without limitation, all applicable
rules and regulations of the Food and Drug Administration (the “FDA”), except in each case as would not,
individually or in the aggregate, have a Material Adverse Effect.

 

(p)         
Regulatory Permits. The Company and each of its Subsidiaries possesses all licenses, certificates, approvals, permits
and other authorizations and supplements or amendments thereto issued by all applicable federal, state, local or foreign regulatory
authorities necessary to conduct their respective businesses (“Material Permits”),
including, without limitation, the FDA, such Material Permits are in full force and effect, and (i) neither
the Company nor any of its Subsidiaries has not received any notice of any adverse finding, warning letter, assertion of noncompliance
with, or adverse proceedings relating to the any such Material Permits; (ii) the Company has no Knowledge of any facts or
circumstances that the Company would reasonably expect to give rise to the revocation or modification of any Material Permits;
(iii) neither the Company nor any of its Subsidiaries has received written notice of any ongoing claim, action, suit, proceeding,
hearing, enforcement, investigation, arbitration or other action from any governmental entity or third party alleging that any
product manufactured by or on behalf of the Company or any of its Subsidiaries or out-licensed by the Company or any of its Subsidiaries
(a “Company Product”), operation or activity related to a Company Product is in violation of any
Applicable Laws or a Material Permit or has any knowledge that any such governmental entity or third party is considering any such
claim, litigation, arbitration, action, suit, investigation or proceeding; (iv) neither the Company nor any of its Subsidiaries
has received written notice that any governmental entity has taken, is taking or intends to take action to limit, suspend, modify
or revoke any Material Permit or has any knowledge that any such governmental entity has threatened or is considering such action
with respect to a Company Product; and (v) the Company and each of its Subsidiaries have filed, obtained, maintained or submitted
all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by
any Applicable Laws or Material Permits and that all such reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments were complete, correct and not misleading on the date filed (or were corrected or supplemented by
a subsequent submission). To the Company’s knowledge, neither the Company nor any of its Subsidiaries, directors, officers,
employees or agents, has made, or caused the making of, any false statements on, or material omissions from, any other records
or documentation prepared or maintained to comply with the requirements of the FDA or any other governmental entity.

 

(q)         
Title to Assets. The Company does not own any real property. The Company and its Subsidiaries have good and marketable
title to all tangible personal property owned by them which is material to the business of the Company and its Subsidiaries, taken
as a whole, in each case free and clear of all Liens except such as do not materially affect the value of such property and do
not materially interfere with the use made and proposed to be made of such property by the Company or its Subsidiaries and except
for Liens for the payment of federal, state or other taxes for which appropriate reserves have been made in accordance with GAAP
and the payment of which is not delinquent or subject to penalties. Any real property and facilities held under lease by the Company
or its Subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions as are not material and
do not materially interfere with the use made of such property and buildings by the Company or its Subsidiaries.

 

    12

     

    

 

(r)         
Intellectual Property. The Company and its Subsidiaries collectively own, possess, license or have other rights to use
all material foreign and domestic patents, patent applications, trade and service marks, trade and service mark registrations,
trade names, copyrights, licenses, inventions, trade secrets, technology, know-how and other proprietary rights and processes necessary
for the conduct of their businesses, taken as a whole, as now conducted or as proposed in the SEC Reports to be conducted (collectively,
the “Intellectual Property”). To the Company’s Knowledge, (i) there are no rights of
third parties to any Intellectual Property, other than as licensed by the Company; (ii) the Company’s or its Subsidiaries’
use of any such Intellectual Property in the conduct of its business as presently conducted does not infringe upon the rights of
any third parties; (ii) there is no infringement by third parties of any such Intellectual Property; (iii) there is no
pending or threatened Action challenging the Company’s rights in or to or scope of any such Intellectual Property; (iv) there
is no pending or threatened Action challenging the validity or scope of any such Intellectual Property; and (v) there is no
pending or threatened Action that the Company infringes or otherwise violates any patent, trademark, copyright, trade secret or
other proprietary rights of others. The Company is not aware of any facts required to be disclosed to the U.S. Patent and Trademark
Office which have not been disclosed to the U.S. Patent and Trademark Office and which would preclude the grant of a patent in
connection with any patent application of the Intellectual Property or could form the basis of a finding of invalidity with respect
to any issued patents of the Intellectual Property.  The Company and its Subsidiaries collectively have taken reasonable security
measures to protect the secrecy, confidentiality and value of all of the Intellectual Property, except where the failure to do
so would not, individually or in the aggregate, have or reasonably be expected to have a Material Adverse Effect.

 

(s)         
Insurance. The Company and each of its Subsidiaries is insured by insurers of recognized financial responsibility against
such losses and risks and in such amounts as are reasonable and customary in the business in which it is engaged; all policies
of insurance and fidelity or surety bonds insuring the Company and each of its Subsidiaries or their respective businesses, assets,
employees, officers and directors are in full force and effect; the Company and each of its Subsidiaries is in compliance with
the terms of such policies and instruments in all material respects; there are no claims by the Company or any of its Subsidiaries
under any such policy or instrument as to which any insurance company is denying liability or defending under a reservation of
rights clause; and neither the Company nor any of its Subsidiaries has been refused any insurance coverage sought or applied for.
The Company has not received any notice of cancellation of any such insurance, nor does the Company have any Knowledge that it
will be unable to renew its existing insurance coverage for the Company as and when such coverage expires or to obtain similar
coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.

 

(t)          
Transactions with Affiliates and Employees. None of the officers or directors of the Company and, to the Company’s
Knowledge, none of the employees of the Company, is presently a party to any transaction with the Company or to a transaction presently
contemplated by the Company (other than for services as employees, officers and directors) that would be required to be disclosed
by the Company pursuant to Item 404 of Regulation S-K promulgated under the Securities Act, except as contemplated by
the Transaction Documents or set forth in the SEC Reports.

 

    13

     

    

 

(u)         
Internal Accounting Controls. The Company maintains a system of internal accounting controls sufficient to provide reasonable
assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset and liability
accountability, (iii) access to assets or incurrence of liabilities is permitted only in accordance with management’s general
or specific authorization, and (iv) the recorded accountability for assets and liabilities is compared with the existing assets
and liabilities at reasonable intervals and appropriate action is taken with respect to any differences. The Company’s internal
controls over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) are effective to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles and the Company is not aware of any material weakness in its internal
controls over financial reporting. 

 

(v)         
Sarbanes-Oxley. Except as disclosed in the SEC Reports, the Company is in compliance in all material respects with all
of the provisions of the Sarbanes-Oxley Act of 2002 which are applicable to it. The Company has established disclosure controls
and procedures (as such term is defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) for the Company and designed such
disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or
submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s
rules and forms. The Company’s certifying officers have evaluated the effectiveness of the Company’s disclosure controls
and procedures as of the end of the period covered by the Company’s most recently filed periodic report under the Exchange
Act (such date, the “Evaluation Date”). The Company presented in its most recently filed periodic report
under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures
based on their evaluations as of the Evaluation Date) and such disclosure controls and procedures are effective. Since the Evaluation
Date, there have been no changes in the Company’s internal control over financial reporting (as such term is defined in the
Exchange Act) that have materially affected, or are reasonably likely to materially affect, the Company’s internal control
over financial reporting.

 

(w)        
Certain Fees. No person or entity will have, as a result of the transactions contemplated by this Agreement, any valid
right, interest or claim against or upon the Company or a Purchaser for any commission, fee or other compensation pursuant to any
agreement, arrangement or understanding entered into by or on behalf of the Company.

 

(x)         
Private Placement. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2
of this Agreement (without giving effect to any materiality qualifiers therein) and the accuracy of the information disclosed by
each Purchaser in the Accredited Investor Questionnaire delivered pursuant to Section 2.2(b)(iv) and Section 5.3(d),
no registration under the Securities Act is required for the offer and sale of the Shares by the Company to the Purchasers under
the Transaction Documents.

 

(y)         
No General Solicitation. Neither the Company nor any Person acting on its behalf has conducted any “general solicitation”
or “general advertising” (as those terms are used in Regulation D) in connection with the offer or sale of any
of the Shares.

 

(z)         
No Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2
(without giving effect to any materiality qualifiers therein), neither the Company nor any Person acting on its behalf has, directly
or indirectly, at any time within the past six (6) months, made any offers or sales of any Company security or solicited any offers
to buy any security under circumstances that would (i) eliminate the availability of the exemption from registration under
Section 4(a)(2) or Regulation D under the Securities Act in connection with the offer and sale by the Company of the Shares
as contemplated hereby or (ii) cause the Offering of the Shares pursuant to the Transaction Documents to be integrated with
prior offerings by the Company for purposes of any applicable law, regulation or shareholder approval provisions, including, without
limitation, under the rules and regulations of any Trading Market on which any of the securities of the Company are listed or designated.

 

    14

     

    

 

(aa)       
Registration Rights. Other than the Purchasers pursuant to the Registration Rights Agreement or as disclosed in Section
3.1(aa) of the Disclosure Schedule, no Person has any right to cause the Company to effect the registration under the Securities
Act of any securities of the Company.

 

(bb)      
Listing and Maintenance Requirements. The Company’s Common Stock is registered pursuant to Section 12(b) of the
Exchange Act, and the Company has taken no action designed to terminate the registration of the Common Stock under the Exchange
Act, nor has the Company received any notification that the Commission is contemplating terminating such registration. There are
no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of
the Company’s common stock on the Principal Trading Market and the Company has not, in the 12 months preceding the date hereof,
received written notice from any Trading Market on which the Common Stock is listed or quoted to the effect that the Company is
not in compliance with the listing or maintenance requirements of such Trading Market. The Company is in compliance with all listing
and maintenance requirements of the Principal Trading Market on the date hereof and the issuance of the Shares will not violate
any such listing or maintenance requirements.

 

(cc)       
Application of Takeover Protections; Rights Agreements. The Company and its board of directors have taken all necessary
action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any
distribution under a rights agreement) or other similar anti-takeover provision under the Company’s charter documents or
the laws of the State of Delaware that is or could reasonably be expected to become applicable to any of the Purchasers as a result
of the Purchasers and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including,
without limitation, the Company’s issuance of the Shares and the Purchasers’ ownership of the Shares. The Company has
not adopted a stockholder rights plan or similar arrangement relating to accumulations of beneficial ownership of Common Stock
or a change in control of the Company.

 

(dd)       
Off Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company and
an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company in its SEC Reports (including,
for purposes hereof, any that are required to be disclosed in a Form 10) and is not so disclosed or that otherwise would have a
Material Adverse Effect.

 

(ee)       
Foreign Corrupt Practices. Neither the Company nor any of its Subsidiaries, nor to the Company’s Knowledge, any
agent or other person acting on behalf of the Company or its Subsidiaries, has: (i) directly or indirectly, used any funds for
unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii)
made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties
or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company (or made by any person acting
on its behalf of which the Company is aware) which is in violation of law or (iv) taken any action, directly or indirectly, that
would result in a violation by the Company or such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules
and regulations thereunder.

 

(ff)        
Money Laundering Laws. The operations of the Company and its Subsidiaries are and have been conducted at all times in
compliance with applicable financial recordkeeping and reporting requirements and the money laundering statutes and the rules and
regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental
agency (collectively, the “Money Laundering Laws”) and no action, suit or proceeding by or before any
court or governmental agency, authority or body or any arbitrator involving the Company or any of its Subsidiaries with respect
to the Money Laundering Laws is pending or, to the Knowledge of the Company, threatened.

 

    15

     

    

 

(gg)      
OFAC. Neither the Company nor any of its Subsidiaries nor, to the Knowledge of the Company, any director, officer, agent
or employee of the Company or any of its Subsidiaries (i) is currently subject to any sanctions administered or imposed by
the United States (including any administered or enforced by the Office of Foreign Assets Control of the U.S. Treasury Department,
the U.S. Department of State, or the Bureau of Industry and Security of the U.S. Department of Commerce), the United Nations Security
Council, the European Union, or the United Kingdom (including sanctions administered or controlled by Her Majesty’s Treasury)
(collectively, “Sanctions” and such persons, “Sanction Persons”) or (ii) will,
directly or indirectly, use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any
subsidiary, joint venture partner or other person in any manner that will result in a violation of any economic Sanctions by, or
could result in the imposition of Sanctions against, any person (including any person participating in the offering, whether as
underwriter, advisor, investor or otherwise). Neither the Company nor any of its Subsidiaries nor, to the Knowledge of the Company,
any director, officer, agent, or employee of the Company or any of its Subsidiaries, is a person that is, or is 50% or more owned
or otherwise controlled by a person that is: (i) the subject of any Sanctions; or (ii) located, organized or resident
in a country or territory that is, or whose government is, the subject of Sanctions that broadly prohibit dealings with that country
or territory (collectively, “Sanctioned Countries” and each, a “Sanctioned Country”).
To the Knowledge of the Company, neither the Company nor any of its Subsidiaries has engaged in any dealings or transactions with
or for the benefit of a Sanctioned Person, or with or in a Sanctioned Country, in the preceding three years, nor does the Company
or its Subsidiaries have any plans to increase their respective dealings or transactions with Sanctioned Persons, or with or in
Sanctioned Countries.

 

(hh)      
Transfer Taxes.  There are no transfer taxes or other similar fees or charges under Federal law or the laws of
any state, or any political subdivision thereof, required to be paid in connection with the execution and delivery of this Agreement
or the issuance by the Company or sale by the Company of the Shares.

 

(ii)        
Investment Company.  The Company is not and, after giving effect to the offering and sale of the Shares, will not
be an “investment company” as defined in the Investment Company Act of 1940, as amended.

 

(jj)        
Price of Common Stock.  The Company has not, and to the Company’s Knowledge no one acting on its behalf has,
taken, directly or indirectly, any action designed to cause or result in, or that has constituted or that might reasonably be expected
to constitute the stabilization or manipulation of the price of any securities of the Company to facilitate the sale or resale
of the Shares.

 

    16

     

    

 

(kk)      
ERISA.  None of the following events has occurred or exists: (i) a failure to fulfill the obligations, if
any, under the minimum funding standards of Section 302 of the United States Employee Retirement Income Security Act of 1974,
as amended (“ERISA”), and the regulations and published interpretations thereunder with respect to a
Plan that is required to be funded, determined without regard to any waiver of such obligations or extension of any amortization
period; (ii) an audit or investigation by the Internal Revenue Service, the U.S. Department of Labor, the Pension Benefit
Guaranty Corporation or any other federal or state governmental agency or any foreign regulatory agency with respect to the employment
or compensation of employees by any of the Company that would reasonably be expected to have a Material Adverse Effect; (iii) any
breach of any contractual obligation, or any violation of law or applicable qualification standards, with respect to the employment
or compensation of employees by the Company that would reasonably be expected to have a Material Adverse Effect. None of the following
events has occurred or is reasonably likely to occur: (i) a material increase in the aggregate amount of contributions required
to be made to all Plans in the current fiscal year of the Company compared to the amount of such contributions made in the most
recently completed fiscal year of the Company; (ii) a material increase in the “accumulated post-retirement benefit
obligations” (within the meaning of Statement of Financial Accounting Standards 106) of the Company compared to the amount
of such obligations in the most recently completed fiscal year of the Company; (iii) any event or condition giving rise to
a liability under Title IV of ERISA that would reasonably be expected to have a Material Adverse Effect; or (iv) the filing
of a claim by one or more employees or former employees of the Company related to their employment that would reasonably be expected
to have a Material Adverse Effect. For purposes of this paragraph, the term “Plan” means a plan (within the meaning
of Section 3(3) of ERISA) subject to Title IV of ERISA with respect to which the Company may have any liability.

 

(ll)        
No “Bad Actor” Disqualification.  To the Company’s Knowledge, no Covered Person is subject to
any of the “bad actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities
Act (“Disqualification Events”), except for a Disqualification Event covered by Rule 506(d)(2) or
(d)(3) under the Securities Act. The Company has complied, to the extent applicable, with any disclosure obligations under
Rule 506(e) under the Securities Act. “Covered Persons” are those persons specified in Rule 506(d)(1) under
the Securities Act, including the Company; any predecessor or affiliate of the Company; any director, executive officer, other
officer participating in the offering, general partner or managing member of the Company; any beneficial owner of 20% or more of
the Company’s outstanding voting equity securities, calculated on the basis of voting power; any promoter (as defined in
Rule 405 under the Securities Act) connected with the Company in any capacity at the time of the sale of the Shares; and any
person that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the
sale of the Shares (a “Solicitor”), any general partner or managing member of any Solicitor, and any
director, executive officer or other officer participating in the offering of any Solicitor or general partner or managing member
of any Solicitor.

 

(mm)    
Registration Eligibility.  To the Knowledge of the Company, the Company is eligible to register the resale of the
Shares by the Purchasers using Form S-3 promulgated under the Securities Act.

 

(nn)      
Disclosure.  The Company understands and confirms that the Purchasers will rely on the foregoing representations
in effecting transactions in securities of the Company. The Disclosure Materials, and all due diligence materials regarding
the Company, its business and the transactions contemplated hereby that are not projections or forward-looking statements, furnished
by or on behalf of the Company to any Purchaser in connection with such Purchaser’s evaluation of the Company are, when taken
together with the Disclosure Materials, true and correct in all material respects and do not contain any untrue statement of a
material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances
under which they were made, not misleading. All projections and forward-looking statements regarding the Company and its business,
furnished by or on behalf of the Company to any Purchaser in connection with such Purchaser’s evaluation of the Company,
were made on a good faith, reasonable basis by Company management.

 

    17

     

    

 

3.2        
Representations and Warranties of the Purchasers. Each Purchaser hereby, for itself and for no other Purchaser, represents
and warrants as of the date hereof and as of the Closing Date to the Company as follows:

 

(a)         
Organization; Authority. Such Purchaser is an entity duly organized, validly existing and in good standing under the
laws of the jurisdiction of its organization with the requisite corporate, partnership, limited liability company or other similar
power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents to which it is a
party and otherwise to carry out its obligations hereunder and thereunder. The execution, delivery and performance by such Purchaser
of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate or, if such Purchaser is
not a corporation, such partnership, limited liability company or other applicable like action, on the part of such Purchaser.
Each Transaction Document to which it is a party has been (or, upon delivery, will have been) duly
executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid
and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except as such enforceability
may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting
generally the enforcement of, creditors’ rights and remedies or by other equitable principles of general application or insofar
as indemnification and contribution provisions may be limited by applicable law.

 

(b)         
Non Contravention. The execution, delivery and performance by such Purchaser of the Transaction Documents to which it
is a party and the consummation by such Purchaser of the transactions contemplated hereby and thereby will not (i) result
in a violation of the organizational documents of such Purchaser, (ii) constitute a default (or an event which with notice
or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or
cancellation of, any agreement, indenture or instrument to which such Purchaser is a party or (iii) result in a violation
of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such Purchaser,
except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not,
individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Purchaser to
perform its obligations hereunder.

 

(c)         
Investment Intent. Such Purchaser understands that the Shares are “restricted securities” and have not been
registered under the Securities Act or any applicable state securities law and is acquiring the Shares as principal for its own
account and not with a view to, or for distributing or reselling such Shares or any part thereof in violation of the Securities
Act or any applicable state securities laws. Such Purchaser is acquiring the Shares hereunder in the ordinary course of its business.
Such Purchaser does not presently have any agreement, plan or understanding, directly or indirectly, with any Person to distribute
or effect any distribution of any of the Shares (or any securities which are derivatives thereof) to or through any person or entity;
such Purchaser is not a registered broker-dealer under Section 15 of the Exchange Act or an entity engaged in a business that
would require it to be so registered as a broker-dealer.

 

(d)         
Purchaser Status. At the time such Purchaser was offered the Shares, it was, and at the date hereof it is, an “accredited
investor” as defined in Rule 501(a) under the Securities Act, for the reason(s) specified on the Accredited Investor Questionnaire
attached hereto as completed by such Purchaser, and such Purchaser shall submit to the Company such further assurances of such
status as may be reasonably requested by the Company.

 

(e)         
General Solicitation. Such Purchaser is not purchasing the Shares as a result of any advertisement, article, notice
or other communication regarding the Shares published in any newspaper, magazine or similar media or broadcast over television
or radio or presented at any seminar or any other general advertisement.

 

(f)         
Experience of Such Purchaser. Such Purchaser, either alone or together with its representatives, has such knowledge,
sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective
investment in the Shares, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic
risk of an investment in the Shares and, at the present time, is able to afford a complete loss of such investment.

 

    18

     

    

 

(g)        
Access to Information. Such Purchaser acknowledges that it has had the opportunity to review the Disclosure Materials
and has been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from,
representatives of the Company concerning the terms and conditions of the Offering of the Shares and the merits and risks of investing
in the Shares; (ii) access to information about the Company and its respective financial condition, results of operations,
business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity
to obtain such additional information that the Company possesses or can acquire without unreasonable
effort or expense that is necessary to make an informed investment decision with respect to the investment. Neither such inquiries
nor any other investigation conducted by or on behalf of such Purchaser or its representatives
or counsel shall modify, amend or affect such Purchaser’s right to rely on the truth, accuracy
and completeness of the Disclosure Materials and the Company’s representations and warranties contained in the Transaction
Documents (as qualified by the Disclosure Materials). Such Purchaser has sought such accounting, legal and tax advice as it has
considered necessary to make an informed decision with respect to its acquisition of the Shares.

 

(h)        
Certain Trading Activities. Other than with respect to the transactions contemplated herein, since the time such Purchaser
was first contacted by the Company or any other Person regarding the transactions contemplated hereby, neither such Purchaser nor
any Affiliate of such Purchaser (including, for purposes of this Section 3.2(h), any limited partner of such Purchaser)
has, directly or indirectly, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser or an
Affiliate of such Purchaser, effected or agreed to effect any transactions in the securities of the Company (including, without
limitation, any Short Sales involving the Company’s securities). Neither such Purchaser nor any Affiliate of such Purchaser
holds any short position in the Company’s securities. Other than to other Persons party to this Agreement or to employees
or advisors of such Purchaser, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with
the transactions contemplated hereby (including the existence and terms of such transactions).

 

(i)          
Brokers and Finders. No Person will have, as a result of the transactions contemplated by this Agreement, any valid
right, interest or claim against or upon the Company or any Purchaser for any commission, fee or other compensation pursuant to
any agreement, arrangement or understanding entered into by or on behalf of such Purchaser.

 

(j)         
Independent Investment Decision. Such Purchaser has independently evaluated the merits of its decision to purchase Shares
pursuant to the Transaction Documents, and such Purchaser confirms that it has not relied on the advice of any other Person’s
business and/or legal counsel in making such decision. Such Purchaser understands that nothing in this Agreement or any other materials
presented by or on behalf of the Company to the Purchaser in connection with the purchase of the Shares constitutes legal, tax
or investment advice. Such Purchaser has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed
necessary or appropriate in connection with its purchase of the Shares.

 

(k)        
Reliance on Exemptions. Such Purchaser understands that the Shares are being offered and sold to it in reliance on specific
exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying
in part upon the truth and accuracy of, and such Purchaser’s compliance with, the representations, warranties, agreements,
acknowledgements and understandings of such Purchaser set forth herein
in order to determine the availability of such exemptions and the eligibility of such Purchaser
to acquire the Shares.

 

    19

     

    

 

(l)         
No Governmental Review. Such Purchaser understands that no United States federal or state agency or any other government
or governmental agency has passed on or made any recommendation or endorsement of the Shares or the fairness or suitability of
the investment in the Shares nor have such authorities passed upon or endorsed the merits of the Offering of the Shares.

 

(m)        
Regulation M. Such Purchaser is aware that the anti-manipulation rules of Regulation M under the Exchange
Act may apply to sales of Common Stock and other activities with respect to the Common Stock by the Purchasers.

 

(n)         
Residency. Such Purchaser’s principal executive offices are in the jurisdiction set forth immediately below such
Purchaser’s name on the signature page attached hereto.

 

(q)          Prohibited
Purchaser. Such Purchaser represents that neither it nor, to its knowledge, any person or entity controlling, controlled by
or under common control with it, nor any person having a beneficial interest in it, nor any person on whose behalf the Purchaser
is acting: (i) is a person listed in the Annex to Executive Order No. 13224 (2001) issued by the President of the United States
(Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism);
(ii) is named on the List of Specially Designated Nationals and Blocked Persons maintained by the U.S. Office of Foreign Assets
Control; (iii) is a non-U.S. shell bank or is providing banking services indirectly to a non-U.S. shell bank; (iv) is a senior
non-U.S. political figure or an immediate family member or close associate of such figure; or (v) is otherwise prohibited from
investing in the Company pursuant to applicable U.S. anti-money laundering, anti-terrorist and asset control laws, regulations,
rules or orders (categories (i) through (v), each a “Prohibited Purchaser”). The Purchaser agrees to
provide the Company, promptly upon request, all information that the Company reasonably deems necessary or appropriate to comply
with applicable U.S. anti-money laundering, anti-terrorist and asset control laws, regulations, rules and orders. The Purchaser
consents to the disclosure to U.S. regulators and law enforcement authorities by the Company and its Affiliates and agents of such
information about the Purchaser as the Company reasonably deems necessary or appropriate to comply with applicable U.S. antimony
laundering, anti-terrorist and asset control laws, regulations, rules and orders. If the Purchaser is a financial institution that
is subject to the USA Patriot Act, the Purchaser represents that it has met all of its obligations under the USA Patriot Act. The
Purchaser acknowledges that if, following its investment in the Company, the Company reasonably believes that the Purchaser is
a Prohibited Purchaser, the Company has the right or may be obligated to prohibit additional investments, segregate the assets
constituting the investment in accordance with applicable regulations or immediately require the Purchaser to transfer the Shares.
The Purchaser further acknowledges that the Purchaser will have no claim against the Company or any of its Affiliates or agents
for any form of damages as a result of any of the foregoing actions.

 

The Company and each
of the Purchasers acknowledge and agree that no party to this Agreement has made or makes any representations or warranties with
respect to the transactions contemplated hereby other than those specifically set forth in this Article III and the Transaction
Documents and that, except as otherwise provided herein, neither the Company nor any Purchaser has relied on the accuracy or completeness
of any information not contained in the Transaction Documents.

 

    20

     

    

 

Article
4

OTHER AGREEMENTS OF THE PARTIES

 

4.1        
Transfer Restrictions.

 

(a)         
Compliance with Laws. Notwithstanding any other provision of the Transaction Documents, each Purchaser covenants that
the Shares may be disposed of only pursuant to an effective registration statement under, and in compliance with the requirements
of, the Securities Act, or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements
of the Securities Act, and in compliance with any applicable state and federal securities laws. In connection with any transfer
of the Shares other than (i) pursuant to an effective registration statement, (ii) to the Company, (iii) pursuant
to Rule 144, or (iv) in connection with a bona fide pledge, the Company may require the transferor thereof to provide
to the Company an opinion of counsel (which, for the avoidance of doubt, may include in-house legal counsel to the Purchaser),
the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does
not require registration of such transferred Shares under the Securities Act, and, as a condition of such transfer, any such transferee
shall agree in writing to be bound by the terms of this Agreement and shall have the rights of a Purchaser under this Agreement
and the Registration Rights Agreement.

 

(b)         
Lock-Up Period; Certain Dispositions. Each Purchaser shall not, directly or indirectly, during the 6-month period immediately
following the Closing Date (the “Lock-Up Period”), (A) sell, offer to sell, solicit offers to buy,
dispose of, loan, pledge or grant any right with respect to (collectively, a “Disposition”)
the Shares or (B) engage in any Short Sales or hedging transactions involving the Company’s securities. In addition, each
Purchaser agrees that for so long as it owns any Common Stock, it will not enter into any Short Sale of Shares executed at a time
when such Purchaser has no equivalent offsetting long position in the Common Stock. For purposes of determining whether such Purchaser
has an equivalent offsetting long position in the Common Stock, shares that such Purchaser is entitled to receive within sixty
(60) days (whether pursuant to contract or upon conversion or exercise of convertible securities) will be included as if held
long by such Purchaser. Each Purchaser covenants that neither it nor any Person acting on its behalf or pursuant to any understanding
with it will engage in any transactions in the Company’s securities (including, without limitation, any Short Sales involving
the Company’s securities) during the period from the date hereof until the earlier of such time as (i) the expiration
of the Lock-Up Period or (ii) this Agreement is terminated in full pursuant to Section 6.16. Each Purchaser understands
and acknowledges, severally and not jointly with any other Purchaser, that the Commission currently takes the position that covering
a short position established prior to effectiveness of a resale registration statement with shares included in such registration
statement would be a violation of Section 5 of the Securities Act, as set forth in Division of Corporation Financing Compliance
and Disclosure Interpretation 239.10 regarding short selling.

 

(c)         
Legends. Certificates evidencing the Shares shall bear any legend as required by the “Blue Sky” laws of
any state and restrictive legends in substantially the following form until such time as they are not required under Section 4.1(d)
(and a stock transfer order may be placed against transfer of the Shares):

 

THESE SECURITIES HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE
STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE
REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT
SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE
SKY LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY AND ITS TRANSFER AGENT OR (II) UNLESS
SOLD PURSUANT TO RULE 144 UNDER SAID ACT.

 

THE SHARES ARE SUBJECT
TO A SIX (6)-MONTH LOCK-UP PERIOD, AS SET FORTH IN A SECURITIES PURCHASE AGREEMENT AMONG THE COMPANY AND THE ORIGINAL HOLDER OF
THESE SHARES, COPIES OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE COMPANY.

 

    21

     

    

 

In addition, if the
Company reasonably determines that any Purchaser is an Affiliate of the Company, the certificate evidencing the Shares issued to
such Purchaser shall bear a customary “Affiliates” legend.

 

(d)         
Removal of Legends. Subject to the Company’s right to request an opinion of counsel as set forth in Section
4.1(a), the legends set forth in Section 4.1(c) above shall be removable and the Company shall remove such legends
or any other legends and issue and cause to be issued to such holder by electronic delivery at the applicable balance account at
The Depository Trust Company (“DTC”) evidence of a book entry position, free and clear of all restrictive
and other legends or instructions as provided in this Section 4.1(d), if, at any time following the expiration of the
Lock-up Period, (i) such Shares are registered for resale under the Securities Act and the Purchaser is selling pursuant to
the effective registration statement registering the Shares for resale (provided that, the Purchaser agrees to only sell such Shares
during such time that such registration statement is effective and not withdrawn or suspended, and only as permitted by such registration
statement), or (ii) such Shares are sold or transferred in compliance with Rule 144 (if the transferor is not an Affiliate of the
Company), including without limitation in compliance with the current public information requirements of Rule 144 if applicable
to the Company at the time of such sale or transfer, and the holder and its broker have delivered customary documents reasonably
requested by the Transfer Agent and/or Company Counsel in connection with such sale or transfer. Any fees (with respect to the
Transfer Agent, Company Counsel or otherwise) associated with the removal of such legend shall be borne by the Company. Following
the Effective Date (as defined in the Registration Rights Agreement), or at such other time as a legend is no longer required for
certain Shares, the Company will no later than three (3) Trading Days following the delivery by a Purchaser to the Company
or the Transfer Agent (with concurrent notice and delivery of copies to the Company) of a legended certificate representing such
Shares (endorsed or with stock powers attached, signatures guaranteed, and otherwise in form necessary to affect the reissuance
and/or transfer, and together with such other customary documents as the Transfer Agent and/or Company Counsel shall reasonably
request), deliver or cause to be delivered to the transferee of such Purchaser or such Purchaser, as applicable, a certificate
representing such Shares that is free from all restrictive and other legends. Certificates for Shares subject to legend removal
hereunder shall be transmitted by the Transfer Agent to the Purchasers, as applicable, by crediting the account of the transferee’s
or Purchaser’s prime broker with DTC.

 

(e)        
Irrevocable Transfer Agent Instructions. The Company shall issue irrevocable instructions to its Transfer Agent, and
any subsequent Transfer Agent, in the form of Exhibit E attached hereto (the “Irrevocable Transfer Agent
Instructions”). The Company represents and warrants that no instruction other than the Irrevocable Transfer Agent
Instructions or instructions consistent therewith or otherwise contemplated hereby or thereby or by the other Transaction Documents
or such other documents as the Transfer Agent may request in connection with any such instructions will be given by the Company
to its Transfer Agent in connection with this Agreement, and that the Shares shall otherwise be freely transferable on the books
and records of the Company as and to the extent provided in and subject to the terms of this Agreement, the other Transaction Documents
and applicable law.

 

(f)         
Acknowledgement. Each Purchaser hereunder acknowledges its primary responsibilities under the Securities Act and accordingly
will not sell or otherwise transfer the Shares or any interest therein without complying with the requirements of the Securities
Act. While the Registration Statement remains effective, each Purchaser hereunder may sell the Shares in accordance with the plan
of distribution contained in the Registration Statement and, if it does so, it will comply therewith and with the related prospectus
delivery requirements unless an exemption therefrom is available. Each Purchaser, severally and not jointly with the other Purchasers,
agrees that if it is notified by the Company in writing at any time that the Registration Statement
registering the resale of the Shares is not effective or that the prospectus included in such Registration Statement no longer
complies with the requirements of Section 10 of the Securities Act, such Purchaser will refrain from selling such Shares until
such time as such Purchaser is notified by the Company that such Registration Statement is effective or such prospectus is compliant
with Section 10 of the Securities Act, unless such Purchaser is able to, and does, sell
such Shares pursuant to an available exemption from the registration requirements of Section 5 of the Securities Act. Each
Purchaser acknowledges that the delivery of the Irrevocable Transfer Agent Instructions and any removal of any legends from certificates
representing the Shares as set forth in this Section 4.1 is predicated on the Company’s reliance upon the Purchaser’s
acknowledgement in this Section 4.1(f).

 

    22

     

    

 

4.2        
Acknowledgment of Dilution. The Company acknowledges that the issuance of the Shares may result in dilution of the outstanding
shares of Common Stock. The Company further acknowledges that its obligations under the Transaction Documents, including without
limitation its obligation to issue the Shares pursuant to the Transaction Documents, are, subject to the terms and conditions expressly
set forth in this Agreement, unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction,
regardless of the effect of any such dilution or any claim the Company may have against any Purchaser and regardless of the dilutive
effect that such issuance may have on the ownership of the other stockholders of the Company.

 

4.3        
Form D and Blue Sky. The Company agrees to timely file a Form D with respect to the Shares as required under
Regulation D and to provide a copy thereof to each Purchaser who requests a copy in writing promptly after such filing. The
Company shall take such action as the Company shall reasonably determine is necessary in order to qualify the Shares for sale to
the Purchasers at the Closing pursuant to this Agreement under applicable securities or “Blue Sky” laws of the states
of the United States (or to obtain an exemption from such qualification), which, subject to the accuracy of the Company’s
and the Purchaser’s representations and warranties set forth herein, shall consist of the submission of all filings and reports
relating to the offer and sale of the Shares pursuant to Rule 506 of Regulation D required under applicable securities or “Blue
Sky” laws of the states of the United States following the Closing Date, and shall provide evidence of any such action so
taken to the Purchasers who request in writing such evidence.

 

4.4        
No Integration. The Company shall not, and shall use its commercially reasonable efforts to ensure that the Affiliates
of the Company shall not, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined
in Section 2 of the Securities Act) that will be integrated with the offer or sale of the Shares in a manner that would require
the registration under the Securities Act of the sale of the Shares to the Purchasers, or that will be integrated with the offer
or sale of the Shares for purposes of the rules and regulations of any Trading Market such that it would require shareholder approval
prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.

 

4.5        
Indemnification.

 

(a)        
Indemnification of the Purchasers. In addition to the indemnity provided in the Registration Rights Agreement, subject
to this Section 4.8, the Company will indemnify and hold each Purchaser and its directors, officers, shareholders,
members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles
notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section
15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members,
partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title) of such controlling Person (each, a “Purchaser Party”) harmless
from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments,
amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such Purchaser
Party may suffer or incur, as a result of or relating to: (1) third party claims against such Purchaser relating to any breach
of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction
Documents, and (2) third party claims against a Purchaser or any of its Affiliates, in any capacity, by any Person who is not an
Affiliate, limited partner, or other investor of such Purchaser, with respect to any of the transactions contemplated by the Transaction
Documents (unless such action is based upon a breach of such Purchaser’s representations, warranties or covenants under the
Transaction Documents or any conduct by such Purchaser which constitutes fraud, gross negligence, willful misconduct or malfeasance).
The Company will not be liable to any Purchaser Party under this Agreement to the extent, but only to the extent that a loss, claim,
damage or liability is attributable to (i) the failure of such Purchaser Party to comply with the covenants and agreements contained
in Section 4.8 below respecting sale of the Shares, (ii) the inaccuracy of any representations made by such Purchaser Party
herein, or (iii) information regarding such Purchaser Party furnished in such Purchaser Party’s Accredited Investor Questionnaire
to the Company by such Purchaser Party.

 

    23

     

    

 

(b)        
Conduct of Indemnification Proceedings. Promptly after receipt by any Person (the “Indemnified Person”)
of notice of any demand, claim or circumstances which would or might give rise to a claim or the commencement of any action, proceeding
or investigation in respect of which indemnity may be sought pursuant to Section 4.8(a), such Indemnified Person shall promptly
notify the Company in writing and the Company shall have the right to assume the defense thereof, including the employment of counsel
reasonably satisfactory to such Indemnified Person and the assumption of the payment of all fees and expenses; provided, however,
that the failure of any Indemnified Person to so notify the Company shall not relieve the Company of its obligations hereunder
except to the extent that the Company is actually and materially prejudiced by such failure to notify. In any such proceeding,
any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the
expense of such Indemnified Person unless: (i) the Company and the Indemnified Person shall have mutually agreed to the retention
of such counsel; (ii) the Company shall have failed promptly to assume the defense of such proceeding or the Company does
not, upon assuming the defense of such proceeding, conduct the defense of such claim actively and diligently; or (iii) the
named parties to any such proceeding (including any impleaded parties) include both such Indemnified Person and the Company, and
such Indemnified Person shall have been advised by counsel that a conflict of interest exists if the same counsel were to represent
such Indemnified Person and the Company; (iv) the claim is based upon any proceeding, indictment, allegation or investigation of
a criminal nature; or (v) the claim seeks an injunction or non-monetary or equitable relief against the Indemnified Person, other
than any such claim that is incidental to the primary claim or claims and not material (in the case of clauses (ii)-(v), if such
Indemnified Party notifies the Company in writing that it elects to employ separate counsel at the expense of the Company, the
Company shall not have the right to assume the defense thereof and such counsel shall be at the expense of the Company). The Company
shall not be liable for any settlement of any proceeding effected without its written consent, which consent shall not be unreasonably
withheld, delayed or conditioned. Without the prior written consent of the Indemnified Person, which consent shall not be unreasonably
withheld, delayed or conditioned, the Company shall not effect any settlement of any pending or threatened proceeding in respect
of which any Indemnified Person is a party, unless such settlement includes an unconditional release
of such Indemnified Person from all liability arising out of such Proceeding and such settlement does not require any Indemnified
Person to perform any covenant or refrain from engaging in any activity or include any non-monetary limitation on the actions of
any Indemnified Person or any of its Affiliates or any admission of fault, violation, culpability, malfeasance or nonfeasance by,
or on behalf of, or liability on behalf of, any such Indemnified Person.

 

4.6        
Listing of Securities. In the time and manner required by the Principal Trading Market, the Company shall prepare and
file with such Trading Market any additional shares listing application that may be required by such Trading Market covering all
of the Shares and shall use its commercially reasonable efforts to take all steps necessary to maintain, so long as any other shares
of Common Stock shall be so listed, such listing.

 

    24

     

    

 

4.7       
Securities Laws Disclosure; Publicity. On or before 9:00 a.m., New York City time, on the Business Day immediately following
the date hereof, the Company shall issue a press release (the “Press Release”) reasonably acceptable
to the Purchasers disclosing all material terms of the transactions contemplated hereby. On or before 5:30 p.m., New York City
time, on the fourth Trading Day immediately following the execution of this Agreement, the Company will file a Current Report on
Form 8-K with the Commission describing the terms of the Transaction Documents (and including as exhibits to such Current Report
on Form 8-K the material Transaction Documents, including, without limitation, this Agreement and the Registration Rights Agreement).
Each Purchaser, severally and not jointly with the other Purchasers, covenants that it will comply with the provisions of any confidentiality
or nondisclosure agreement executed by it and, in addition, until such time as the transactions contemplated by this Agreement
are required to be publicly disclosed by the Company as described in this Section 4.7, such Purchaser will maintain the
confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction).

 

Article
5

CONDITIONS PRECEDENT TO CLOSING

 

5.1       
Conditions Precedent to the Obligations of the Purchasers to Purchase Shares at the Closing. The obligation of each
Purchaser to acquire Shares at the Closing is subject to the fulfillment, on or prior to the Closing Date, of each of the following
conditions, any of which may be waived by such Purchaser (as to itself only):

 

(a)         
Representations and Warranties. The representations and warranties made by the Company in Section 3.1 shall be
true and correct in all material respects (except for those representations and warranties which are qualified as to materiality,
in which case such representations and warranties shall be true and correct in all respects) as of the
date when made and as of the Closing Date, as though made on and as of such date, except for such representations and warranties
that speak as of a different specified date.

 

(b)        
Performance. The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements
and conditions required by the Transaction Documents to be performed, satisfied or complied with by it at or prior to the Closing.

 

(c)        
No Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted,
entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation
of any of the transactions contemplated by the Transaction Documents.

 

(d)        
Consents. The Company shall have obtained in a timely fashion any and all consents, permits, approvals, registrations
and waivers necessary for consummation of the purchase and sale of the Shares at the Closing (including all Required Approvals,
except for those set forth in clauses (i), (ii) and (iii) of Section 3.1(e), which may be obtained after the Closing),
all of which shall be and remain so long as necessary in full force and effect.

 

(e)         
No Suspensions of Trading in Common Stock. The Common Stock shall not have been suspended, as of the Closing Date,
by the Commission.

 

(f)         
Company Deliverables. The Company shall have delivered the Company Deliverables in accordance with Section 2.2(a).

 

    25

     

    

 

(g)         
Termination. This Agreement shall not have been terminated in accordance with Section 6.16 herein.

 

5.2        
Conditions Precedent to the Obligations of the Company to sell Shares at the Closing. The Company’s obligation
to sell and issue the Shares to each Purchaser at the Closing is subject to the fulfillment on or prior to the Closing Date of
the following conditions, any of which may be waived by the Company:

 

(a)        
Representations and Warranties. The representations and warranties made by such Purchaser in Section 3.2
hereof shall be true and correct in all material respects (except for those representations and warranties which are qualified
as to materiality, in which case such representations and warranties shall be true and correct in all respects), as of the date
when made and as of the Closing Date as though made on and as of such date except for representations and warranties that speak
as of a different specified date.

 

(b)         
Performance. Such Purchaser shall have performed, satisfied and complied in all material respects with all covenants,
agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by such Purchaser at
or prior to the Closing Date.

 

(c)        
No Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted,
entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction that
prohibits the consummation of any of the transactions contemplated by the Transaction Documents.

 

(d)         
Purchaser Deliverables. Such Purchaser shall have delivered its Purchaser Deliverables in accordance with Section 2.2(b).

 

(e)         
Consents. Such Purchaser shall have obtained in a timely fashion any and all consents, permits, approvals, registrations
and waivers necessary from any governmental authorities necessary for consummation of the purchase and sale of the Shares at the
Closing.

 

(f)          
Termination. This Agreement shall not have been terminated in accordance with Section 6.16 herein.

 

Article
6

MISCELLANEOUS

 

6.1       
Fees and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, the Company and the Purchasers
shall each pay the fees and expenses of their respective advisers, counsel, accountants and other experts, if any, and all other
expenses incurred by such party in connection with the negotiation, preparation, execution, delivery and performance of this Agreement.
The Company shall pay all Transfer Agent fees, stamp taxes and other taxes and duties levied in connection
with the sale and issuance of the Shares to the Purchasers.

 

6.2        
Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding
of the parties with respect to the subject matter thereof and supersede all prior agreements, understandings, discussions and representations,
oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and
schedules. At or after the Closing, and without further consideration, the Company and the Purchasers will execute and deliver
to the other such further documents as may be reasonably requested in order to give practical effect to the intention of the parties
under the Transaction Documents.

 

    26

     

    

 

6.3       
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall
be in writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication
is delivered via facsimile at the facsimile number specified in this Section prior to 5:00 p.m., Boston time, on a Trading Day,
(b) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the
facsimile number specified in this Section on a day that is not a Trading Day or later than 5:00 p.m., Boston time, on any Trading
Day, (c) the Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service with
next day delivery specified, or (d) upon actual receipt by the party to whom such notice is required to be given. The address
for such notices and communications shall be as follows:

 

		If to the Company:	Corindus Vascular Robotics, Inc.

309 Waverley Oaks Road, Suite 105

Waltham, MA 02452

Telephone No.: (508) 653-3335

Facsimile No.: (508) 232-6000

Attention: Chief Executive Officer

 

With a copy to:

 

Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, P.C.

One Financial Center

Boston, Massachusetts 02111

Telephone No.: (617) 348-1799

Facsimile No.: (617) 542-2241

Attention: William C. Hicks, Marc
D. Mantell

 

To the address
set forth under such Purchaser’s name on its signature page hereto.

 

or such other address as may be designated
in writing hereafter, in the same manner, by such Person.

 

6.4        
Amendments; Waivers; No Additional Consideration. No provision of this Agreement may be waived or amended except in
a written instrument signed, in the case of an amendment, by the Company and the Purchasers holding or having the right to acquire
at least a majority of the Shares to be purchased at the Closing or then outstanding or, in the case of a waiver, by the party
against whom enforcement of any such waiver is sought; provided, however, that the Company may amend Exhibit A (without
the consent of the Purchasers holding or having the right to acquire at least a majority of the Shares to be purchased at the Closing
or then outstanding) solely for the purposes of adding additional Purchasers prior to the Closing Date. No waiver of any default
with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future
or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay
or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right.

 

6.5        
Construction. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not
be deemed to limit or affect any of the provisions hereof. The language used in this Agreement will be deemed to be the language
chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. This
Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or
disfavoring any party by virtue of the authorship of any provisions of this Agreement or any of the Transaction Documents.

 

    27

     

    

 

6.6       
Successors and Assigns. The provisions of this Agreement shall inure to the benefit of and be binding upon the parties
and their successors and permitted assigns. This Agreement, or any rights or obligations hereunder, may not be assigned by the
Company without the prior written consent of the Purchasers (other than by merger or consolidation or to an entity which acquires
the Company, including by way of acquiring all or substantially all of the Company’s assets). Any Purchaser may assign its
rights hereunder in whole or in part to any Person to whom such Purchaser assigns or transfers any Shares in compliance with the
Transaction Documents and applicable law, provided such transferee shall agree in writing to be bound, with respect to the transferred
Shares, by the terms and conditions of this Agreement that apply to the Purchasers.

 

6.7        
No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective
successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

6.8       
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement
shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to
the principles of conflicts of law thereof. Each party agrees that all Proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party
hereto or its respective Affiliates, employees or agents) shall be commenced exclusively in the Boston Courts. Each party hereto
hereby irrevocably submits to the exclusive jurisdiction of the Boston Courts for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement
of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Proceeding, any claim that
it is not personally subject to the jurisdiction of any such Boston Court, or that such Proceeding has been commenced in an improper
or inconvenient forum. Each party hereto hereby irrevocably waives personal service of process and consents to process being served
in any such Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good
and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to
serve process in any manner permitted by law. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY
APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE
TRANSACTIONS CONTEMPLATED HEREBY.

 

6.9        
Survival. The representations and warranties contained herein shall survive the Closing and the delivery of the Shares
for a period of one (1) year from the Closing Date. Covenants to be performed after the Closing shall survive until performed or
observed in accordance with their terms.

 

6.10      
Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other
party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by
facsimile transmission, or by e-mail delivery of a “.pdf” format data file, such signature shall create
a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect
as if such facsimile or “.pdf” signature page were an original thereof.

 

    28

     

    

 

6.11     
Severability. If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity
and enforceability of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby
and the parties will attempt to agree upon a valid and enforceable provision that is a reasonable substitute therefor and achieves
that same or substantially the same effect or result, and upon so agreeing, shall incorporate such substitute provision in this
Agreement.

 

6.12      
Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery
of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The
parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations
described in the foregoing sentence and hereby agree to waive in any action for specific performance of any such obligation (other
than in connection with any action for a temporary restraining order) the defense that a remedy at law would be adequate.

 

6.13     
Payment Set Aside. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction
Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement
or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from,
disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person
under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action),
then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived
and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.

 

6.14     
Adjustments in Share Numbers and Prices. In the event of any stock split, subdivision, dividend or distribution payable
in shares of Common Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly
or indirectly shares of Common Stock), reverse stock split, combination or other similar recapitalization or event occurring after
the date hereof, each reference in any Transaction Document to a number of shares or a price per share shall be deemed to be amended
to appropriately account for such event.

 

6.15      
Waiver of Conflicts. Each Purchaser acknowledges that: (a) it has read this Agreement; (b) it has been represented in
the preparation, negotiation and execution of this Agreement by legal counsel of its own choice or has voluntarily declined to
seek such counsel; and (c) it understands the terms and consequences of this Agreement and is fully aware of the legal and binding
effect of this Agreement. Each Purchaser understands that the Company has been represented in the preparation, negotiation and
execution of this Agreement by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Company Counsel, and that Mintz, Levin, Cohn,
Ferris, Glovsky and Popeo, P.C. has not represented any Purchaser or any stockholder, director or employee of the Company in the
preparation, negotiation and execution of this Agreement. Each Purchaser acknowledges that Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, P.C. may have in the past represented and may now or may in the future represent one or more Purchasers or their Affiliates
in matters unrelated to the transactions contemplated by this Agreement, including the representation of such Purchasers or their
Affiliates in matters of a nature similar to those contemplated by this Agreement. The Company and each Purchaser hereby acknowledge
that they have has had an opportunity to ask for and have obtained information relevant to such representation, including disclosure
of the reasonably foreseeable adverse consequences of such representation, and hereby waives any conflict arising out of such representation
with respect to the matters contemplated by this Agreement.

 

    29

     

    

 

6.16      
Termination. This Agreement may be terminated and the sale and purchase of the Shares abandoned at any time prior to
the Closing by either the Company or any Purchaser (with respect to itself only) upon written notice to the other, if the Closing
has not been consummated on or prior to 5:00 p.m., Boston time, on the Outside Date; provided, however, that the
right to terminate this Agreement under this Section 6.16 shall not be available to any Person whose failure to comply with
its obligations under this Agreement has been the primary cause of or resulted in the failure of the Closing to occur on or before
such time. Nothing in this Section 6.16 shall be deemed to release any party from any liability for any breach by such party
of the terms and provisions of this Agreement or the other Transaction Documents or to impair the right of any party to compel
specific performance by any other party of its obligations under this Agreement or the other Transaction Documents. Upon a termination
in accordance with this Section 6.16, the Company and the Purchaser shall not have any further obligation or liability (including
arising from such termination) to the other. The Company and Purchasers may extend the term of this Agreement in accordance with
the amendment provisions of Section 6.4 herein.

 

[Remainder of Page Intentionally Left
Blank; Signature Page Follows]

 

    30

     

    

 

In
Witness Whereof, the parties hereto have caused this Common Stock
Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

 

	 	COMPANY:
	 	 	 
	 	CORINDUS VASCULAR ROBOTICS, INC.
	 	 	 
	 	By: 	 
	 	Name:  	 
	 	Title:  	 

  

[Signature Pages
for Purchasers Follow]

 

[Signature Page to Securities Purchase Agreement]

 

     

     

    

 

	 	PURCHASER:
	 	 
	 	[____________________] 
	 	 
	 	By: 	 
	 	 	Name:
	 	 	Title:
	 	 	 
	 	Aggregate Purchase Price (Subscription Amount):
	 	 
	 	Number of Shares of Common Stock to be Acquired:
	 	 
	 	 	 
	 	 	 
	 	Address for Notice/Residency of Purchaser:
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

	 	Telephone No.:	 

 

	 	Facsimile No.:	 

 

	 	E-mail Address:	 

 

	 	Attention:	 

 

Delivery Instructions:

(if different than above)

 

	c/o	 	 

 

	Street:	 	 

 

	City/State/Zip:	 	 

 

	Attention:	 	 

 

	Telephone No.:	 	 

 

[Signature Page to Securities Purchase Agreement]

 

     

     

    

 

EXHIBITS:

 

		A:	Schedule of Purchasers

		B	Form of Registration Rights Agreement

		C-1:	Accredited Investor Questionnaire

		C-2:	Stock Certificate Questionnaire

		D:	Form of Opinion of Company Counsel

		E:	Irrevocable Transfer Agent Instructions

		F:	Form of Secretary’s Certificate

		G:	Form of Compliance Certificate

 

     

     

    

 

Exhibit A

 

Schedule of Purchasers

 

	Purchaser	Subscription Amount
	 	 
	 	 
	 	 

 

    A-1 

     

    

 

Exhibit C-1

 

Form of Accredited Investor
Questionnaire

 

ACCREDITED INVESTOR QUESTIONNAIRE

(ALL INFORMATION WILL BE TREATED CONFIDENTIALLY)

 

		To:	Corindus Vascular Robotics, Inc.

 

This Investor Questionnaire (“Questionnaire”)
must be completed by each potential investor in connection with the offer and sale of the shares of the common stock, par value
$0.0001 per share, (the “Securities”), of Corindus Vascular Robotics, Inc., a Delaware corporation (the
“Corporation”). The Securities are being offered and sold by the Corporation without registration under
the Securities Act of 1933, as amended (the “Act”), and the securities laws of certain states, in reliance
on the exemptions contained in Section 4(a)(2) of the Act and on Regulation D promulgated thereunder and in reliance on similar
exemptions under applicable state laws. The Corporation must determine that a potential investor meets certain suitability requirements
before offering or selling Securities to such investor. The purpose of this Questionnaire is to assure the Corporation that each
investor will meet the applicable suitability requirements. The information supplied by you will be used in determining whether
you meet such criteria, and reliance upon the private offering exemptions from registration is based in part on the information
herein supplied.

 

This Questionnaire does not constitute
an offer to sell or a solicitation of an offer to buy any security. Your answers will be kept strictly confidential. However, by
signing this Questionnaire, you will be authorizing the Corporation to provide a completed copy of this Questionnaire to such parties
as the Corporation deems appropriate in order to ensure that the offer and sale of the Securities will not result in a violation
of the Act or the securities laws of any state and that you otherwise satisfy the suitability standards applicable to purchasers
of the Securities. All potential investors must answer all applicable questions and complete, date and sign this Questionnaire.
Please print or type your responses and attach additional sheets of paper if necessary to complete your answers to any item.

 

		PART A.	BACKGROUND INFORMATION

 

	Name of Beneficial Owner of the Securities: 	 

 

	Business Address: 	 
	 	(Number and Street)

 

	(City)	(State)	(Zip Code)

 

	Telephone Number: (___) 	 

   

If a corporation, partnership, limited liability company,
trust or other entity:

 

Type of entity:__________________

	State of formation: __________________	Approximate Date of formation: __________________

 

Were you formed for the purpose of
investing in the securities being offered?

 

Yes ____          No ____

 

    C-1-1 

     

    

 

If an individual:

 

	Residence Address: 	 
	 	(Number and Street)

 

	(City)	(State)	(Zip Code)

 

Telephone Number: (____)___________

 

	Age:__________	Citizenship: ____________	Where registered
to vote: _______________

 

Set forth in the space provided below the
state(s), if any, in the United States in which you maintained your residence during the past two years and the dates during which
you resided in each state:

 

Are you a director or executive officer
of the Corporation?

 

Yes ____          No ____

 

Social Security or Taxpayer Identification No.: _________________________

 

		PART B.	ACCREDITED INVESTOR QUESTIONNAIRE

 

In order for the Corporation
to offer and sell the Securities in conformance with state and federal securities laws, the following information must be obtained
regarding your investor status. Please initial each category applicable to you as a Purchaser of Securities of the Corporation.

 

		___ (1)	A bank as defined
in Section 3(a)(2) of the Securities Act, or any savings and loan association or other institution as defined in Section 3(a)(5)(A)
of the Securities Act whether acting in its individual or fiduciary capacity;

 

		___ (2)	A broker or dealer registered pursuant to Section 15
of the Securities Exchange Act of 1934;

 

		___ (3)	An insurance company as defined in Section 2(a)(13) of
the Securities Act;

 

		___ (4)	An investment company registered under the Investment
Company Act of 1940 or a business development company as defined in Section 2(a)(48) of such act;

 

		___ (5)	A Small Business Investment Company licensed by the U.S.
Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958;

 

		___ (6)	A plan established and maintained by a state, its political
subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if
such plan has total assets in excess of $5,000,000;

 

		___ (7)	An employee benefit plan within the meaning of the Employee
Retirement Income Security Act of 1974, if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of
such act, which is either a bank, savings and loan association, insurance company, or registered investment adviser, or if the
employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made solely
by persons that are accredited investors;

 

    C-1-2 

     

    

 

		___ (8)	A private business development company as defined in
Section 202(a)(22) of the Investment Advisers Act of 1940;

 

		___ (9)	An organization described in Section 501(c)(3) of the
Internal Revenue Code, a corporation, Massachusetts or similar business trust, or partnership, not formed for the specific purpose
of acquiring the Securities, with total assets in excess of $5,000,000;

 

		___ (10)	A trust, with total assets in excess of $5,000,000, not
formed for the specific purpose of acquiring the Securities, whose purchase is directed by a sophisticated person who has such
knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of investing
in the Corporation;

 

		___ (11)	A natural person whose individual net worth, or joint
net worth with that person’s spouse, at the time of his purchase exceeds $1,000,000 (excluding the value of such persons’
primary residence);

 

		___ (12)	A natural person who had an individual income in excess
of $200,000 in each of the two most recent years, or joint income with that person’s spouse in excess of $300,000, in each
of those years, and has a reasonable expectation of reaching the same income level in the current year;

 

		___ (13)	An executive officer or director of the Corporation;

 

		___ (14)	An entity in which all of the equity owners qualify under
any of the above subparagraphs. If the undersigned belongs to this investor category only, list the equity owners of the undersigned,
and the investor category which each such equity owner satisfies.

 

[Remainder of Page Intentionally Left
Blank; Signature Page Follows]

 

    C-1-3 

     

    

 

		A.	FOR EXECUTION BY AN INDIVIDUAL:

 

	 	By	 	 	 	 
	 	 	 	 	 	 
	 	Date	 	 	 
	 	 	 	 	 	 
	 	Print Name:	 

 

		B.	FOR EXECUTION BY AN ENTITY:

 

	 	Entity Name:	 	 
	 	 	 	 	 	 
	 	By	 	 	 	 
	 	 	 	 	 	 
	 	Date	 	 	 
	 	 	 	 	 	 
	 	Print Name:	 
	 	 	 	 	 	 
	 	Title:	 	 	 

  

		C.	ADDITIONAL SIGNATURES (if required by partnership, corporation or trust document):

 

	 	Entity Name:	 	 
	 	 	 	 	 	 
	 	By	 	 	 	 
	 	 	 	 	 	 
	 	Date	 	 	 
	 	 	 	 	 	 
	 	Print Name:	 
	 	 	 	 	 	 
	 	Title:	 	 	 

 

	 	Entity Name:	 	 
	 	 	 	 	 	 
	 	By	 	 	 	 
	 	 	 	 	 	 
	 	Date	 	 	 
	 	 	 	 	 	 
	 	Print Name:	 
	 	 	 	 	 	 
	 	Title:	 	 	 

 

     

     

    

 

Exhibit C-2

 

Form of Stock Certificate
Questionnaire

 

Stock Certificate Questionnaire

 

Pursuant to Section 2.2(b)(vi) of the Agreement, please provide
us with the following information:

 

1.           The exact name that
the Securities are to be registered in (this is the name that will appear on the stock certificate(s)). You may use a nominee name
if appropriate:

 

	 
	 
	 
	 
	 

 

2.           The relationship
between the Purchaser of the Securities and the Registered Holder listed in response to Item 1 above:

 

	 
	 
	 
	 
	 

 

3.           The mailing address,
telephone and telecopy number of the Registered Holder listed in response to Item 1 above:

 

	 
	 
	 
	 
	 

 

4.           The Tax Identification
Number (or, if an individual, the Social Security Number) of the Registered Holder listed in response to Item 1 above:

 

	 
	 
	 
	 
	 

 

    C-2-1 

     

    

 

Exhibit E

 

Form of Irrevocable Transfer
Agent Instructions

 

CORINDUS VASCULAR ROBOTICS, INC.

 

March____, 2019

Manhattan Transfer Registrar Company

57 Eastwood Road

Miller Place, New York 11764

Attn: Ms. Desirée Carlo

 

Ladies and Gentlemen:

 

Reference is made to
that certain Securities Purchase Agreement, dated as of March ___, 2019 (the “Agreement”), by and
among Corindus Vascular Robotics, Inc., a Delaware corporation (the “Company”), and the purchasers
named therein (collectively, and including permitted transferees, the “Holders”), pursuant to which the
Company is issuing to the Holders shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”).

 

By this letter, you
are irrevocably authorized and directed to issue an aggregate of [●] shares of the Company’s Common Stock (the “Shares”).
The Shares should be issued in the names and denominations specified on Schedule I hereto, in either book entry or stock
certificate form, as indicated on Schedule I. The Shares have not been registered and are, therefore, “restricted
shares.” Accordingly, the Shares should bear the following restricted legend:

 

THESE SECURITIES HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES
MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE
SECURITIES UNDER THE SECURITIES ACT OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION
OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY AND ITS TRANSFER AGENT OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT.

 

The Shares are also
subject to certain restrictions on transfer in accordance with the Agreement during the six (6)-month period following the closing
of the sale of the Shares (the “Lock-Up Period”). Accordingly, the Shares should bear the following restricted
legend:

 

THE SHARES ARE SUBJECT TO A SIX (6)-MONTH
LOCK-UP PERIOD, AS SET FORTH IN A SECURITIES PURCHASE AGREEMENT AMONG THE COMPANY AND THE ORIGINAL HOLDER OF THESE SHARES, COPIES
OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE COMPANY.

 

The Shares may be issued
to any Holder in certificate form (each, a “Certificate” and collectively, the “Certificates”)
upon request. Any Certificate issued should contain the aforementioned legend.

 

    E-1 

     

    

 

This letter shall also
serve as our irrevocable authorization and direction to you (provided that you are the transfer agent of the Company at such time
and the conditions set forth in this letter are satisfied), subject to any stop transfer instructions that we may issue to you
from time to time, if any, to issue shares of Common Stock upon transfer or resale of the Shares.

 

You acknowledge and
agree that so long as (i) you have received written confirmation from the Company’s legal counsel that a registration statement
covering resales of the Shares has been declared effective by the Securities and Exchange Commission (the “Commission”)
under the Securities Act of 1933, as amended (the “Securities Act”), and a copy of such registration
statement, and (ii) the Lock-Up Period has expired, then, unless otherwise required by law, you shall use your commercially reasonable
efforts to issue the certificates representing the Shares registered in the names of such Holders or transferees, as the case may
be, within three (3) Business Days of your receipt of a notice of transfer of Shares, and such certificates shall not bear any
legend restricting transfer of the Shares thereby and should not be subject to any stop-transfer restriction.

 

A form of written confirmation
from the Company’s outside legal counsel that a registration statement covering resales of the Shares has been declared effective
by the Commission under the Securities Act (which confirmation shall be delivered to you upon effectiveness of the registration
statement) is attached hereto as Annex A.

 

Please be advised that
the Holders are relying upon this letter as an inducement to enter into the Agreement and, accordingly, each Holder is a third
party beneficiary to these instructions.

 

Please execute this letter in the space
indicated to acknowledge your agreement to act in accordance with these instructions.

 

[Remainder of Page Intentionally Left
Blank; Signature Page Follows]

 

    E-2 

     

    

 

	 	Very truly yours,
	 	 	 
	 	CORINDUS VASCULAR ROBOTICS, INC.
	 	 	 
	 	By: 	
	 	Name: 	Mark J. Toland
	 	Title:  	Chief Executive Officer and President

 

Acknowledged and Agreed:

 

	Manhattan Transfer Registrar Company	 
	 	 	 	 	 
	By:	 	 	 	 
	Name:	 	 
	Title:	 	 	 

 

[Signature Page to Authorization Letter
to Transfer Agent]

 

     

     

    

 

Schedule
I

 

Holders

 

	Holders	Address	EIN	Common

Shares	Form
	[●]	[●]	[●]	[●]	[●]

 

    Schedule I-1 

     

    

 

Annex
A

 

FORM OF NOTICE OF EFFECTIVENESS OF REGISTRATION
STATEMENT

 

Manhattan Transfer Registrar Company

57 Eastwood Road

Miller Place, New York 11764

Attn: Ms. Desirée Carlo

 

Re: Corindus Vascular Robotics, Inc.

 

Ladies and Gentlemen:

 

Corindus Vascular Robotics,
Inc., a Delaware corporation (the “Company”), has entered into a Securities Purchase Agreement (the “Agreement”),
dated as of [●], 2019, with the buyers named therein (collectively, the “Purchasers”) pursuant
to which the Company issued to the Purchasers shares of the Company’s common stock, $0.0001 par value per share (the “Common
Stock”). Pursuant to that certain Registration Rights Agreement of even date, the Company agreed to register the
resale of the Common Stocks (the “Registrable Securities”), under the Securities Act of 1933, as
amended (the “Securities Act”). In connection with the Company’s obligations under the Registration
Rights Agreement, on [___], 2019, the Company filed a Registration Statement on Form S-3 (File No. 333-                    )
(the “Registration Statement”) with the Securities and Exchange Commission (the “Commission”)
relating to the Registrable Securities which names each of the Purchasers as a selling stockholder thereunder and set forth as
Exhibit A hereto.

 

In connection with
the foregoing, we advise you that a member of the Commission’s staff has advised us by telephone that the Commission has
entered an order declaring the Registration Statement effective under the Securities Act at ____ [a.m.][p.m.] on [___], 2019, and
we have no knowledge, after telephonic inquiry of a member of the staff, that any stop order suspending its effectiveness has been
issued or that any proceedings for that purpose are pending before, or threatened by, the Commission and the Registrable Securities
are available for resale under the Securities Act pursuant to the Registration Statement. Based upon the foregoing, we are of the
opinion that as of the date of this opinion, the Registrable Securities have been duly authorized and, when issued by you, will
be validly issued, fully paid and non-assessable, and are registered for resale under the Securities Act under the effective Registration
Statement and, following the expiration of the Lock-Up Period (as defined in the Agreement), may be issued without a restrictive
legend.

 

This letter shall serve
as our standing notice to you that, following the expiration of the Lock-Up Period, the Common Stock may be freely transferred
by the Purchasers pursuant to the Registration Statement. You need not require further letters from us to effect any future legend-free
issuance or reissuance of shares of Common Stock upon the expiration of the Lock-Up Period to the Purchasers or the transferees
of the Purchasers, as the case may be, as contemplated by the Company’s Irrevocable Transfer Agent Instructions dated [●],
2019, provided at the time of such reissuance, the Company has not otherwise notified you that the Registration Statement is unavailable
for the resale of the Registrable Securities. This letter shall serve as our standing instructions with regard to this matter.

 

[Remainder of Page Intentionally
Left Blank; Signature Page Follows]

 

    Annex A-1 

     

    

 

	 	Very truly yours,
	 	 	 
	 	CORINDUS VASCULAR ROBOTICS, INC.
	 	 	 
	 	By: 	 
	 	Name:	 Mark J. Toland
	 	Title: 	Chief Executive Officer and President

 

[Signature Page to Notice of Effectiveness
of Registration Statement]

 

     

     

    

 

Exhibit
A

 

Registration
Statement

 

    A-1 

     

    

 

Exhibit F

 

Form of Secretary’s
Certificate

 

corindus
vascular robotics, Inc.

 

Secretary’s Certificate

 

March _____, 2019

 

The undersigned
hereby certifies that he is the duly elected, qualified and acting Secretary of Corindus Vascular Robotics, Inc., a Delaware
corporation (the “Company”), and that as such he is authorized to execute and deliver this
certificate in the name and on behalf of the Company, pursuant to Section 2.2(a)(v) of the Securities Purchase Agreement,
dated as of March ____, 2019, by and among the Company and the purchasers party thereto (the “Securities
Purchase Agreement”), and further certifies in his official capacity, in the name and on behalf of the Company, the items set
forth below. Capitalized terms used but not otherwise defined herein shall have the meaning set forth in the Securities Purchase
Agreement.

 

		1.	Attached hereto as Exhibits A-1 and A-2 are true, correct and complete copies of
the resolutions duly adopted by the Board of Directors of the Company and any duly authorized committee thereof by unanimous written
consent dated March 8, 2019 approving the transactions contemplated by the Securities Purchase Agreement and the other Transaction
Documents and the issuance of the Securities. Such resolutions have not in any way been amended, modified, revoked or rescinded,
have been in full force and effect since their adoption and are now in full force and effect and are the only resolutions adopted
by the Board of Directors of the Company or any duly authorized committee thereof relating to the transactions contemplated by
the Transaction Documents.

 

		2.	Attached hereto as Exhibit B-1 is a true, correct and complete copy of the Certificate of
Incorporation of the Company, together with any and all amendments thereto, and no action has been taken to further amend, modify
or repeal such Certificate of Incorporation, the same being in full force and effect as of the date hereof. Attached hereto as
Exhibit B-2 is a true, correct and complete copy of the Bylaws of the Company, together with any and all amendments thereto,
and no action has been taken to further amend, modify or repeal such Bylaws, the same being in full force and effect as of the
date hereof.

 

		3.	Each person whose name appears on Exhibit C hereto is duly elected or appointed to the position(s)
indicated opposite his name and is duly authorized to sign the Transaction Documents and any related documents on behalf of the
Company, and the signature appearing opposite such person’s name is such person’s genuine signature.

 

[Remainder of Page Intentionally Left
Blank; Signature Page Follows]

 

    F-1 

     

    

 

IN WITNESS WHEREOF,
the undersigned have executed this certificate as of the date first set forth above.

 

	 	By: 	 
	 	Name: 	David W. Long
	 	Title:	Secretary

 

I, Mark J. Toland,
Chief Executive Officer and President, hereby certify that David W. Long is the duly elected, qualified and acting Secretary of
the Company and that the signature set forth above is his true signature.

 

	 	By: 	 
	 	Name: 	 Mark J. Toland
	 	Title:	Chief Executive Officer and President

 

    F-2 

     

    

 

Exhibit A-1

 

Board Resolutions

 

    F-2

     

    

 

Exhibit A-2

 

Committee Resolutions

 

    F-3

     

    

 

Exhibit B-1

 

Certificate of Incorporation

 

    F-4

     

    

 

Exhibit B-2

 

Bylaws

 

    F-5

     

    

 

Exhibit C

 

Certificate of Incumbency

 

	Name	Title	Signature
	 	 	 
	Mark J. Toland	Chief Executive Officer and President	 
	 	 	 
	David W. Long	Chief Financial Officer and Senior Vice

 President, Secretary and Treasurer 	 

 

    F-6

     

    

 

Exhibit G

 

Form of Compliance Certificate

 

Corindus
vascular robotics, Inc.

 

Compliance Certificate

 

March _____, 2019

 

The undersigned, the
Chief Executive Officer and President of Corindus Vascular Robotics, Inc., a Delaware corporation (the “Company”),
pursuant to Section 2.2(a)(vi) of the Securities Purchase Agreement, dated as of March ___, 2019, by and among the Company and
Purchasers (as defined therein) (the “Securities Purchase Agreement”), hereby represents, warrants
and certifies as follows (capitalized terms used but not otherwise defined herein shall have the meaning set forth in the Securities
Purchase Agreement):

 

		1.	The representations and warranties made by the Company in Section 3.1 of the Securities Purchase
Agreement are true and correct in all material respects (except for those representations and warranties which are qualified as
to materiality, in which case such representations and warranties are true and correct in all respects) as of the date when made
and as of the date hereof; as though made on and as of such date, except for such representations and warranties that speak as
of a different specified date.

 

		2.	The Company has performed, satisfied and complied in all material respects with all covenants,
agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by it at or prior to
the date hereof.

 

[Remainder of Page Intentionally Left
Blank; Signature Page Follows]

 

    G-1

     

    

 

IN WITNESS WHEREOF,
the undersigned has executed this certificate as of the date first set forth above.

 

	 	 	 
	 	Mark J. Toland	 
	 	Chief Executive Officer and President	 

 

    G-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]